CASEID,PRIMARYID,CASEVERSION,I_F_CODE,EVENT_DT,MFR_DT,INIT_FDA_DT,FDA_DT,REPT_COD,AUTH_NUM,MFR_NUM,MFR_SNDR,LIT_REF,AGE,AGE_COD,AGE_GRP,SEX,E_SUB,WT,WT_COD,REPT_DT,TO_MFR,OCCP_COD,REPORTER_COUNTRY,OCCR_COUNTRY,DRUGNAME,PT,PRIMARYID_OUTC,OUTC_COD,PRIMARYID_RPSR,RPSR_COD,PRIMARYID_THER,DSG_DRUG_SEQ,START_DT,END_DT,DUR,DUR_COD,PRIMARYID_INDI,INDI_DRUG_SEQ,INDI_PT
11739131,117391312,2,F,,20151029,20151113,20200310,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-17476250,BRISTOL MYERS SQUIBB,,1,DY,,,Y,,,20200310,,HP,FR,FR,SUSTIVA,Foetal exposure during pregnancy;Pachygyria,117391312,CA,,,,,,,,,117391312,1,Product used for unknown indication
11739295,117392952,2,F,,20151029,20151113,20200311,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18707307,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20200311,,HP,FR,FR,EFAVIRENZ.,Congenital central nervous system anomaly;Foetal exposure during pregnancy,117392952,CA,,,,,,,,,117392952,1,Product used for unknown indication
11748560,117485602,2,F,,20151112,20151117,20200311,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-18707349,BRISTOL MYERS SQUIBB,,,,N,,Y,,,20200311,,HP,FR,FR,SUSTIVA,Congenital cerebral cyst;Foetal exposure during pregnancy,117485602,CA,,,,,,,,,117485602,1,Product used for unknown indication
11991033,1199103310,10,F,,20200305,20160202,20200317,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-004939,BRISTOL MYERS SQUIBB,,54,YR,,M,Y,,,20200317,,CN,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,1199103310,OT,,,,,,,,,1199103310,1,Product used for unknown indication
13598440,135984402,2,F,20100126,20170516,20170531,20200312,EXP,,US-MYLANLABS-2017M1032035,MYLAN,,0,DY,,,Y,2.98,KG,20200312,,HP,US,US,EFAVIRENZ W/EMTRICITABINE/TENOFOVIR DISOPROXI,Foetal exposure during pregnancy;Polydactyly,135984402,CA,,,,,,,,,135984402,1,Product used for unknown indication
14235560,142355603,3,F,,20200310,20171129,20200320,EXP,,IN-AUROBINDO-AUR-APL-2017-43833,AUROBINDO,,38,YR,,M,Y,,,20200320,,HP,IN,IN,EFAVIRENZ.,Acarodermatitis;Bulbar palsy;Condition aggravated;Guillain-Barre syndrome;Immune reconstitution inflammatory syndrome;Muscular weakness;Rash;Rash papular,142355603,OT,,,,,,,,,142355603,1,HIV infection
14797478,147974782,2,F,,20191230,20180424,20200110,EXP,,US-LUPIN PHARMACEUTICALS INC.-2018-00403,LUPIN,,,,A,M,Y,,,20200110,,HP,US,US,EFAVIRENZ.,Acute kidney injury,147974782,OT,,,147974782,3,20141101,,,,147974782,1,HIV infection
15027468,150274682,2,F,,20200102,20180619,20200110,EXP,,IT-AUROBINDO-AUR-APL-2018-031662,AUROBINDO,,16,YR,,M,Y,,,20200111,,HP,IT,IT,EFAVIRENZ.,Drug resistance;Toxicity to various agents;Viral mutation identified,150274682,OT,,,,,,,,,150274682,1,HIV infection
15027477,150274772,2,F,,20200102,20180619,20200110,EXP,,IT-AUROBINDO-AUR-APL-2018-031687,AUROBINDO,,17,YR,,F,Y,,,20200111,,HP,IT,NG,EFAVIRENZ.,Drug resistance;Toxicity to various agents;Viral mutation identified,150274772,OT,,,,,,,,,150274772,1,HIV infection
15027629,150276292,2,F,,20200102,20180619,20200110,EXP,,IT-AUROBINDO-AUR-APL-2018-031684,AUROBINDO,,18,YR,,F,Y,,,20200111,,HP,IT,IT,EFAVIRENZ.,Drug resistance;Toxicity to various agents;Viral mutation identified,150276292,OT,,,,,,,,,150276292,1,HIV infection
15114149,1511414912,12,F,20171006,20200214,20180706,20200221,EXP,,GB-AUROBINDO-AUR-APL-2018-033634,AUROBINDO,,,,,M,Y,,,20200221,,CN,GB,GB,Efavirenz Film-coated Tablet,Abortion spontaneous;Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18;Ultrasound antenatal screen,1511414912,OT,,,1511414912,1,20171006,20180205,,,1511414912,1,Product used for unknown indication
15123625,1512362523,23,F,20180205,20200207,20180710,20200213,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-060524,BRISTOL MYERS SQUIBB,,43,YR,,F,Y,,,20200213,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Intentional product use issue;Maternal exposure during pregnancy,1512362523,OT,,,1512362523,1,20171006,20180205,,,1512362523,1,HIV infection
15123626,1512362619,19,F,20180112,20200207,20180710,20200213,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-063878,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200213,,CN,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,1512362619,CA,,,1512362619,1,20171006,,,,1512362619,1,Product used for unknown indication
15158165,151581659,9,F,20171006,20200207,20180718,20200218,EXP,,GB-AUROBINDO-AUR-APL-2018-036078,AUROBINDO,,43,YR,,F,Y,,,20200218,,CN,GB,GB,Efavirenz Film-coated Tablet,Abortion spontaneous;Hydrops foetalis;Intentional product use issue;Maternal exposure during pregnancy,151581659,OT,,,151581659,1,20171006,,,,151581659,1,HIV infection
15317962,153179625,5,F,20171006,20200316,20180824,20200324,EXP,,PHHY2018GB074559,NOVARTIS,,,,,M,Y,,,20200324,,CN,GB,GB,EFAVIRENZ.,Cleft lip and palate;Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,153179625,CA,,,153179625,2,20171006,20180205,,,153179625,1,Foetal exposure during pregnancy
15335320,153353207,7,F,20060216,20200210,20180830,20200214,EXP,,PHHY2009FR075292,NOVARTIS,,,,N,F,Y,,,20200214,,CN,FR,FR,EFAVIRENZ.,Anencephaly;Brain herniation;Congenital hydrocephalus;Encephalocele;Foetal exposure during pregnancy;Meningomyelocele;Neural tube defect;Spina bifida;Spinocerebellar disorder,153353207,OT,,,153353207,1,20050523,20050908,,,153353207,1,Foetal exposure during pregnancy
15357443,153574436,6,F,20171006,20200114,20180906,20200123,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-NOVOPROD-619477,NOVO NORDISK,,43,YR,,F,Y,,,20200124,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,153574436,OT,,,153574436,2,20171006,20180205,,,153574436,1,Product used for unknown indication
15357909,153579098,8,F,20171006,20200316,20180906,20200324,EXP,GB-AUROBINDO-AUR-APL-2018-033634,PHHY2018GB086977,NOVARTIS,,43,YR,,F,Y,,,20200324,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Intentional product use issue,153579098,OT,,,153579098,2,20171006,20180205,,,153579098,1,Product used for unknown indication
15488801,154888015,5,F,,20200113,20181011,20200121,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-090269,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20200121,,HP,AT,AT,EFAVIRENZ.,Acute stress disorder;Intentional product use issue;Live birth;Maternal exposure during pregnancy;Premature rupture of membranes,154888015,OT,,,,,,,,,154888015,1,Antiretroviral therapy
15626751,156267518,8,F,,20200309,20181116,20200313,EXP,,CA-ABBVIE-18S-028-2552613-00,ABBVIE,,54,YR,,M,Y,,,20200313,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,156267518,DE,,,,,,,,,156267518,1,HIV infection
15630483,156304833,3,F,,20200113,20181119,20200123,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2018-104504,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20200123,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,156304833,OT,,,,,,,,,156304833,1,HIV infection
15920383,159203833,3,F,,20200116,20190205,20200121,EXP,,CA-TEVA-2019-CA-1007031,TEVA,,52,YR,,M,Y,,,20200121,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,159203833,OT,,,,,,,,,159203833,1,HIV infection
15962439,159624397,7,F,20181001,20200130,20190214,20200207,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2018GSK236781,VIIV,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G ET AL.. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;DOI: 10.1056/NEJMOA1905230",,,,,Y,,,20200207,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159624397,OT,,,159624397,1,20170330,,,,159624397,1,HIV infection
15962440,159624407,7,F,20181001,20200130,20190214,20200207,EXP,,BW-GLAXOSMITHKLINE-BW2018GSK236781,GLAXOSMITHKLINE,"ZASH R, HOLMES L, DISEKO M, JACOBSON DL, BRUMMEL S, MAYONDI G ET AL.. NEURAL-TUBE DEFECTS AND ANTIRETROVIRAL TREATMENT REGIMENS IN BOTSWANA. THE NEW ENGLAND JOURNAL OF MEDICINE. 2019;DOI: 10.1056/NEJMOA1905230",,,,,Y,,,20200207,,MD,BW,BW,EFAVIRENZ.,Foetal death;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,159624407,DE,,,159624407,1,20170330,,,,159624407,1,HIV infection
15966138,159661383,3,F,,20200203,20190215,20200211,EXP,,PT-009507513-1902PRT002788,MERCK,,43,YR,,M,Y,,,20200211,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,159661383,OT,,,,,,,,,159661383,1,Hepatitis C
16022512,160225126,6,F,,20191219,20190301,20200101,EXP,,CA-AUROBINDO-AUR-APL-2019-010641,AUROBINDO,,52,YR,,M,Y,,,20200101,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,160225126,CA,,,,,,,,,160225126,1,HIV infection
16032571,160325714,4,F,,20200124,20190304,20200130,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-019003,BRISTOL MYERS SQUIBB,MENDEZ J. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS. PRESENTED AT CO-INFECTION PORTUGUESE STUDY GROUP. 2019,43,YR,,M,Y,,,20200130,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,160325714,OT,,,,,,,,,160325714,1,HIV test positive
16043054,160430543,3,F,20180806,20200304,20190306,20200311,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2019GSK039654,VIIV,,29,YR,,F,Y,,,20200311,,MD,UG,UG,EFAVIRENZ.,Suicidal ideation,160430543,LT,,,160430543,1,20180328,20180403,,,160430543,1,HIV infection
16064738,160647386,6,F,20171006,20191105,20190312,20200204,EXP,,GB-MYLANLABS-2019M1022917,MYLAN,,43,YR,,F,Y,,,20200204,,MD,GB,GB,EFAVIRENZ.,Abortion spontaneous;Hydrops foetalis;Maternal exposure during pregnancy,160647386,OT,,,160647386,1,20171006,20180205,,,160647386,1,HIV infection
16064851,160648516,6,F,2017,20200211,20190312,20200217,EXP,,US-ABBVIE-19K-163-2698768-00,ABBVIE,,71,YR,,M,Y,73.55,KG,20200217,,CN,US,US,SUSTIVA,Axillary mass;Axillary pain;Cataract;Decreased appetite;Erectile dysfunction;Infection;Mobility decreased;Nasopharyngitis;Neoplasm;Neoplasm skin;Pain;Psoriasis;Psoriatic arthropathy;Rhinitis;Skin discolouration;Subcutaneous abscess;Weight increased;Wound secretion,160648516,OT,,,160648516,1,20150504,201901,,,160648516,1,Psoriatic arthropathy
16081150,160811505,5,F,,20200312,20190316,20200320,EXP,,CA-AUROBINDO-AUR-APL-2019-013361,AUROBINDO,,54,YR,,M,Y,,,20200320,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,160811505,OT,,,,,,,,,160811505,1,HIV infection
16112768,161127684,4,F,20181128,20200106,20190325,20200110,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2018GSK218858,VIIV,,4,MON,,M,Y,,,20200110,,MD,UG,UG,EFAVIRENZ.,Sickle cell disease,161127684,LT,,,161127684,1,20180522,201810,,,161127684,1,HIV infection
16155546,161555462,2,F,,20200117,20190404,20200127,EXP,,PT-AUROBINDO-AUR-APL-2019-017912,AUROBINDO,,29,YR,,F,Y,,,20200127,,HP,PT,PT,Efavirenz;Emtricitabine;Tenofovir disoproxil fumarate,Exposure during pregnancy;Live birth;Pathogen resistance;Treatment noncompliance;Viral mutation identified;Virologic failure,161555462,OT,,,161555462,7,201707,,,,161555462,1,HIV infection
16170692,161706923,3,F,,20200203,20190408,20200207,EXP,,AT-MYLANLABS-2019M1031449,MYLAN,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R, ET AL... RALTEGRAVIR IN PREGNANCY: A CASE SERIES PRESENTATION.. INTERNATIONAL JOURNAL OF STD + AIDS.. 2011;22(6):350-60",39,YR,,F,Y,,,20200207,,HP,AT,AT,EFAVIRENZ.,Acute stress disorder;Drug abuse;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,161706923,HO,,,,,,,,,161706923,1,Antiretroviral therapy
16186606,161866062,2,F,,20190401,20190411,20200331,EXP,,ZA-GILEAD-2019-0401093,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200331,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161866062,CA,,,,,,,,,161866062,1,HIV infection
16186618,161866182,2,F,,20190401,20190411,20200331,EXP,,ZA-GILEAD-2019-0401788,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200331,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161866182,CA,,,,,,,,,161866182,1,HIV infection
16186720,161867202,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401790,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867202,CA,,,,,,,,,161867202,1,HIV infection
16186723,161867232,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401796,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867232,OT,,,,,,,,,161867232,1,HIV infection
16186724,161867242,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401789,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867242,OT,,,,,,,,,161867242,1,HIV infection
16186725,161867252,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401792,GILEAD,,,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867252,OT,,,,,,,,,161867252,1,HIV infection
16186726,161867262,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401791,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867262,OT,,,,,,,,,161867262,1,HIV infection
16186727,161867272,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401797,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867272,CA,,,,,,,,,161867272,1,HIV infection
16186735,161867352,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401793,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867352,OT,,,,,,,,,161867352,1,HIV infection
16186736,161867362,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401794,GILEAD,,,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867362,OT,,,,,,,,,161867362,1,HIV infection
16186737,161867372,2,F,,20190401,20190411,20200323,EXP,,ZA-GILEAD-2019-0401795,GILEAD,"LE ROUX SM, ABRAMS EJ, DONALD KA, BRITTAIN K, PHILLIPS TK, NGUYEN KK, ZERBE A, KROON M, MYER L. GROWTH TRAJECTORIES OF BREASTFED HIV-EXPOSED UNINFECTED AND HIV-UNEXPOSED CHILDREN UNDER CONDITIONS OF UNIVERSAL MATERNAL ANTIRETROVIRAL THERAPY: A PROSPECTIVE STUDY. LANCET CHILD ADOLESC HEALTH. 2019;3 (4):234-244. DOI:10.1016/S2352-4642(19)30007-0",,,I,,Y,,,20200323,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Microcephaly,161867372,CA,,,,,,,,,161867372,1,HIV infection
16302622,163026223,3,F,,20200120,20190513,20200203,EXP,,GB-CIPLA LTD.-2019GB02975,CIPLA,,,,,,Y,,,20200203,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Hydrops foetalis,163026223,OT,,,163026223,2,20171006,,,,163026223,1,HIV infection
16338358,163383582,2,F,201310,20200320,20190521,20200326,EXP,,US-GILEAD-2019-0408525,GILEAD,,45,YR,A,M,Y,,,20200326,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Pain,163383582,OT,,,163383582,1,2008,201208,,,163383582,1,HIV infection
16345806,163458063,3,F,20130601,20200319,20190523,20200326,PER,,US-GILEAD-2019-0409080,GILEAD,,50,YR,A,M,Y,89.21,KG,20200326,,CN,US,US,SUSTIVA,Chronic kidney disease;Hepatic enzyme increased;Hydronephrosis;Renal failure,163458063,HO,,,163458063,1,20110629,201709,,,163458063,1,HIV infection
16346032,163460324,4,F,20171006,20200122,20190523,20200129,EXP,,GB-TEVA-2019-GB-1052525,TEVA,,43,YR,,F,Y,,,20200129,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,163460324,OT,,,163460324,3,20171006,20180205,,,163460324,1,Product used for unknown indication
16446145,164461453,3,F,,20200106,20190618,20200108,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK105240,VIIV,,54,YR,,M,Y,,,20200108,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,164461453,DE,,,,,,,,,164461453,1,HIV infection
16446152,164461523,3,F,,20200106,20190618,20200108,EXP,,CA-GLAXOSMITHKLINE-CA2019GSK105240,GLAXOSMITHKLINE,,54,YR,,M,Y,,,20200108,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,164461523,DE,,,,,,,,,164461523,1,HIV infection
16457895,164578954,4,F,20190530,20200129,20190620,20200205,EXP,,ZW-VIIV HEALTHCARE LIMITED-ZW2018GSK214194,VIIV,,19,YR,,F,Y,44.4,KG,20200205,,MD,ZW,ZW,EFAVIRENZ.,Back pain;Exposure during pregnancy;Headache;Live birth;Pneumonia,164578954,OT,,,164578954,1,20170321,20181123,,,164578954,1,HIV infection
16457897,164578974,4,F,20190530,20200129,20190620,20200205,EXP,,ZW-GLAXOSMITHKLINE-ZW2018GSK214194,GLAXOSMITHKLINE,,19,YR,,F,Y,44.4,KG,20200205,,MD,ZW,ZW,EFAVIRENZ.,Back pain;Exposure during pregnancy;Headache;Live birth;Pneumonia,164578974,OT,,,164578974,1,20170321,20181123,,,164578974,1,HIV infection
16470789,164707896,6,F,,20200115,20190624,20200122,EXP,,UG-MYLANLABS-2019M1058216,MYLAN,,,,,F,Y,3.7,KG,20200122,,HP,UG,UG,EFAVIRENZ/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE TABLETS,Congenital skin dimples;Congenital umbilical hernia;Foetal exposure during pregnancy,164707896,OT,,,164707896,1,20170721,20180614,,,164707896,1,HIV infection
16549483,165494832,2,F,,20191228,20190710,20200108,EXP,,CA-AUROBINDO-AUR-APL-2019-037892,AUROBINDO,,54,YR,,M,Y,,,20200109,,CN,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,165494832,OT,,,,,,,,,165494832,1,Product used for unknown indication
16636844,166368442,2,F,,20200226,20190726,20200306,EXP,,PT-MYLANLABS-2019M1069166,MYLAN,"MENDEZ, J.. EVALUATION OF THE POPULATION OF COINFECTED HCV/HIV PATIENT NON RESPONDANT TO DAAS.. PRESENTED AT CO-INFECTION PORTUGUESE STUDY GROUP.. 2019;UNK:UNK",43,YR,,M,Y,,,20200306,,MD,PT,PT,EFAVIRENZ.,Hepatitis C;Treatment failure,166368442,OT,,,,,,,,,166368442,1,Hepatitis C
16649549,166495492,2,F,2012,20200212,20190730,20200219,EXP,,"AT-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2019-12-002333",BOEHRINGER INGELHEIM,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,69,YR,,M,Y,90,KG,20200219,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166495492,OT,,,166495492,1,20120419,20121203,,,166495492,1,Antiretroviral therapy
16663673,166636735,5,F,2012,20200226,20190802,20200306,EXP,,AT-JNJFOC-20190735116,JOHNSON AND JOHNSON,SCHALK H. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019;22:.,69,YR,,M,Y,90,KG,20200306,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166636735,OT,,,166636735,1,20111107,20120419,,,166636735,1,Antiviral treatment
16666980,166669802,2,F,201311,20200320,20190805,20200326,EXP,,US-GILEAD-2019-0421690,GILEAD,,40,YR,A,M,Y,73.47,KG,20200326,,LW,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,166669802,OT,,,166669802,1,200601,201002,,,166669802,1,HIV infection
16671350,166713504,4,F,2012,20200224,20190806,20200304,EXP,,AT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-073480,BRISTOL MYERS SQUIBB,SCHALK WH. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019;2:22,69,YR,,M,Y,90,KG,20200304,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,166713504,OT,,,166713504,1,20040423,20140606,,,166713504,1,Antiretroviral therapy
16674551,166745514,4,F,,20200115,20190806,20200211,EXP,,AT-VIIV HEALTHCARE LIMITED-AT2019139261,VIIV,,39,YR,,F,Y,,,20200211,,HP,AT,AT,EFAVIRENZ.,Acute stress disorder;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,166745514,HO,,,,,,,,,166745514,1,Antiretroviral therapy
16674552,166745524,4,F,,20200115,20190806,20200211,EXP,,AT-GLAXOSMITHKLINE-AT2019139261,GLAXOSMITHKLINE,,39,YR,,F,Y,,,20200211,,HP,AT,AT,EFAVIRENZ.,Acute stress disorder;Exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,166745524,HO,,,,,,,,,166745524,1,Antiretroviral therapy
16761858,167618582,2,F,201210,20200317,20190830,20200327,EXP,,US-GILEAD-2019-0425666,GILEAD,,48,YR,A,M,Y,267,KG,20200327,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Multiple injuries;Pain;Pain in extremity;Renal failure;Tooth fracture;Tooth loss,167618582,OT,,,167618582,1,2002,201202,,,167618582,1,HIV infection
16774600,167746002,2,F,20180209,20200317,20190905,20200324,EXP,,US-GILEAD-2019-0425686,GILEAD,,54,YR,A,M,Y,72.56,KG,20200324,,LW,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Depression;Economic problem;Emotional distress;Multiple injuries;Osteoporosis;Pain,167746002,HO,,,167746002,1,201807,201901,,,167746002,1,HIV infection
16785413,167854134,4,F,,20200115,20190909,20200128,EXP,,AT-ROCHE-2394721,ROCHE,"TAYLOR N, TOUZEAU V, GEIT M, GISINGER M, EGLE A, GREIL R ET AL. RALTEGRAVIR IN PREGNANCY: A CASE SERIES PRESENTATION.. INTERNATIONAL JOURNAL OF STD AND AIDS. 2011;22(6):350-360.",39,YR,,F,Y,,,20200128,,HP,AT,AT,EFAVIRENZ.,Acute stress disorder;Maternal exposure during pregnancy;Premature rupture of membranes;Rebound effect;Viral load increased,167854134,HO,,,,,,,,,167854134,1,Antiretroviral therapy
16800956,168009563,3,F,1996,20200316,20190912,20200324,EXP,,PHHY2019ES207545,NOVARTIS,,38,YR,,M,Y,,,20200324,,HP,ES,ES,EFAVIRENZ.,Bone metabolism disorder;Chronic kidney disease;Dyslipidaemia;Fanconi syndrome acquired;Glycosuria;Hypophosphataemia;Lipodystrophy acquired;Musculoskeletal pain;Neurotoxicity;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,168009563,OT,,,168009563,10,2001,2001,,,168009563,1,Antiretroviral therapy
16810112,168101122,2,F,20050822,20200317,20190916,20200324,EXP,,US-GILEAD-2019-0428023,GILEAD,,48,YR,A,M,Y,136.51,KG,20200324,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,168101122,OT,,,168101122,1,200904,201606,,,168101122,1,HIV infection
16838569,168385692,2,F,,20200115,20190923,20200121,EXP,,CA-ABBVIE-19K-028-2932164-00,ABBVIE,,,,,M,Y,,,20200121,,HP,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,168385692,OT,,,,,,,,,168385692,1,Product used for unknown indication
16846431,168464312,2,F,,20200123,20190924,20200124,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019AMR168959,VIIV,,,,,M,Y,,,20200124,,HP,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,168464312,OT,,,,,,,,,168464312,1,Product used for unknown indication
16856140,168561403,3,F,,20200113,20190926,20200115,PER,,US-PFIZER INC-2019411166,PFIZER,,49,YR,,M,Y,94.8,KG,20200115,,MD,US,US,SUSTIVA,Drug interaction;White blood cell count decreased,,,,,,,,,,,168561403,2,HIV infection
16859830,168598306,6,F,,20200306,20190927,20200312,EXP,,FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2019-092601,BRISTOL MYERS SQUIBB,,,,,M,Y,3.23,KG,20200312,,MD,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocele,168598306,OT,,,168598306,1,20070403,20070510,,,168598306,1,Product used for unknown indication
16937381,169373812,2,F,,20200116,20191018,20200122,EXP,,CA-TEVA-2019-CA-1124072,TEVA,,52,YR,,M,Y,,,20200122,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,169373812,OT,,,,,,,,,169373812,1,HIV infection
16938068,169380682,2,F,,20200306,20191018,20200310,EXP,,CA-TEVA-2019-CA-1123923,TEVA,,45,YR,,M,Y,,,20200310,,HP,CA,CA,EFAVIRENZ.,Bone pain;Hypophosphataemia;Musculoskeletal deformity;Osteomalacia;Renal tubular dysfunction,169380682,DS,,,,,,,,,169380682,1,HIV infection
16939572,169395722,2,F,,20200116,20191021,20200121,EXP,,CA-TEVA-2019-CA-1123997,TEVA,,52,YR,,M,Y,,,20200121,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,169395722,CA,,,,,,,,,169395722,1,HIV infection
16944576,169445762,2,F,,20200116,20191022,20200123,EXP,,CA-TEVA-2019-CA-1123953,TEVA,,52,YR,,M,Y,,,20200123,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,169445762,OT,,,,,,,,,169445762,1,HIV infection
16962939,169629392,2,F,,20200129,20191025,20200131,EXP,,ZA-GILEAD-2019-0434474,GILEAD,"MEHTA UC, VAN SCHALKWYK C, NAIDOO P, RAMKISSOON A, MHLONGO O, MAHARAJ NR, NAIDOO N, FIEGGEN K, URBAN MF, KROG S, WELTE A, DHEDA M, PILLAY Y, MORAN NF. BIRTH OUTCOMES FOLLOWING ANTIRETROVIRAL EXPOSURE DURING PREGNANCY: INITIAL RESULTS FROM A PREGNANCY EXPOSURE REGISTRY IN SOUTH AFRICA. SOUTH AFR J HIV MED. 2019;20(1):971-982. DOI:10.4102/SAJHIVMED.V20I1.971",,,N,,Y,,,20200131,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Foetal exposure during pregnancy;Meningomyelocele,169629392,OT,,,,,,,,,169629392,1,HIV infection
17044956,170449562,2,F,,20200106,20191118,20200113,EXP,,CA-BAUSCH-BL-2019-058588,BAUSCH AND LOMB,,54,YR,,M,Y,,,20200113,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,170449562,OT,,,,,,,,,170449562,1,Bipolar disorder
17075956,170759562,2,F,20031224,20200316,20191126,20200324,EXP,,US-GILEAD-2019-0439500,GILEAD,,63,YR,A,M,Y,,,20200324,,CN,US,US,EFAVIRENZ + EMTRICITABINE + TENOFOVIR DISOPROXIL FUMARATE;SUSTIVA,Anhedonia;Anxiety;Bone density decreased;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Foot fracture;Hand fracture;Hip fracture;Osteonecrosis;Osteopenia;Osteoporosis;Pain;Renal failure;Rib fracture,170759562,OT,,,170759562,1,20020730,20050901,,,170759562,1,HIV infection
17075964,170759643,3,F,201009,20200313,20191126,20200320,EXP,,US-GILEAD-2019-0439491,GILEAD,,53,YR,A,M,Y,,,20200320,,CN,US,US,EFAVIRENZ.,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain,170759643,OT,,,170759643,1,20020823,20101201,,,170759643,1,HIV infection
17125266,171252663,3,F,,20200122,20191207,20200129,EXP,,GB-AUROBINDO-AUR-APL-2019-103281,AUROBINDO,,,,,,Y,,,20200129,,CN,GB,GB,Efavirenz Film-coated Tablet,Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,171252663,CA,,,171252663,2,20171006,,,,171252663,1,Product used for unknown indication
17129467,171294672,2,F,2012,20200312,20191209,20200319,EXP,,AT-MYLANLABS-2019M1119555,MYLAN,SCHALK H.. DUAL ART AND MANAGEMENT OF ADVERSE EVENTS. JATROS INFECTIOLOGY + GASTROENETROLOGY-HEPATOLOGY. 2019,69,YR,,M,Y,90,KG,20200319,,MD,AT,AT,EFAVIRENZ.,Abnormal dreams;Asthenia;Decreased appetite;Depressed mood;Diarrhoea;Dizziness;Dyspepsia;Erectile dysfunction;Fatigue;Hyperphagia;Nausea;Renal impairment;Vertigo;Vomiting;Weight increased,171294672,OT,,,171294672,1,20040423,201708,,,171294672,1,Antiretroviral therapy
17162493,171624933,3,F,2008,20200313,20191217,20200317,EXP,,US-GILEAD-2019-0442861,GILEAD,,,,A,M,Y,107.03,KG,20200317,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteopenia;Pain,171624933,OT,,,171624933,1,200411,201701,,,171624933,1,HIV infection
17187134,171871342,2,F,,20200210,20191220,20200214,EXP,,JP-GILEAD-2019-0443510,GILEAD,,37,YR,A,M,Y,,,20200214,,MD,JP,JP,EFAVIRENZ.,Immune reconstitution inflammatory syndrome associated tuberculosis,171871342,HO,,,,,,,,,171871342,1,HIV test positive
17214260,172142602,2,F,1996,20200229,20191230,20200309,EXP,,ES-MYLANLABS-2019M1127115,MYLAN,,38,YR,,M,Y,,,20200309,,HP,CL,ES,EFAVIRENZ.,Asthenia;Bone metabolism disorder;Bone pain;Chronic kidney disease;Drug abuse;Dyslipidaemia;Fanconi syndrome acquired;Fatigue;Glycosuria;Hypophosphataemia;Intentional product misuse;Lipodystrophy acquired;Medication error;Musculoskeletal pain;Musculoskeletal toxicity;Myalgia;Nephropathy toxic;Overdose;Pathological fracture;Proteinuria;Renal impairment;Virologic failure,172142602,OT,,,172142602,1,2002,2010,,,172142602,1,Antiretroviral therapy
17218270,172182703,3,F,20171006,20200114,20191231,20200127,EXP,GB-EMA-DD-20180827-ASHWINIHVP-120514,GB-EMCURE PHARMACEUTICALS LTD-2018-EPL-0507,EMCURE,,43,YR,,F,Y,,,20200127,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,172182703,OT,,,172182703,3,20171006,20180205,,,172182703,1,Product used for unknown indication
17220559,172205593,3,F,,20200125,20191231,20200129,EXP,,ES-MYLANLABS-2019M1132018,MYLAN,,,,A,,Y,,,20200129,,HP,ES,ES,EFAVIRENZ.,Disseminated tuberculosis;Drug interaction;Hepatotoxicity;Neurotoxicity,172205593,OT,,,172205593,1,2008,,,,172205593,1,Antiretroviral therapy
17222298,172222981,1,I,20191221,,20191231,20191231,DIR,,,FDA-CTU,,64,YR,,M,N,,,20191231,N,PH,US,US,EFAVIRENZ.,Gastric perforation;Impaired healing,172222981,HO,172222981,HP,172222981,1,20190131,,,,172222981,1,HIV infection
17222306,172223061,1,I,20191221,,20191231,20191231,DIR,,,FDA-CTU,,64,YR,,M,N,,,20191231,N,PH,US,US,EFAVIRENZ.,Gastric perforation;Impaired healing,172223061,HO,172223061,HP,172223061,1,20190131,,,,172223061,1,HIV infection
17222608,172226082,2,F,20171006,20200108,20200102,20200122,EXP,,GB-IPCA LABORATORIES LIMITED-IPC-2019-GB-002333,IPCA,,,,,,Y,,,20200122,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,172226082,OT,,,172226082,2,20171006,20180205,,,172226082,1,Product used for unknown indication
17223228,172232281,1,I,,20191219,20200102,20200102,EXP,,CA-AUROBINDO-AUR-APL-2019-107311,AUROBINDO,,,,,M,Y,,,20200102,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,172232281,OT,,,,,,,,,172232281,1,Product used for unknown indication
17223371,172233711,1,I,,20191218,20200102,20200102,EXP,,CA-ROCHE-2504137,ROCHE,,44,YR,,M,Y,,,20200102,,HP,CA,CA,SUSTIVA,Anxiety;Depression;Depression suicidal;Paranoia;Psychiatric decompensation;Psychomotor retardation;Psychotic disorder;Suicidal ideation;Tearfulness,172233711,HO,,,,,,,,,172233711,1,Depression
17228741,172287411,1,I,,20191224,20200103,20200103,EXP,,TH-GLAXOSMITHKLINE-TH2019GSK235930,GLAXOSMITHKLINE,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS ONE. 2019;14 (12):DOI.ORG/10.1371/JOURNAL.PONE.0",23,YR,,M,Y,101,KG,20200103,,HP,TH,TH,EFAVIRENZ.,Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic fibrosis;Hepatic function abnormal;Hepatic steatosis;Nonalcoholic fatty liver disease,172287411,OT,,,,,,,,,172287411,1,Perinatal HIV infection
17228745,172287451,1,I,,20191224,20200103,20200103,EXP,,TH-VIIV HEALTHCARE LIMITED-TH2019GSK235930,VIIV,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS ONE. 2019;14 (12):DOI.ORG/10.1371/JOURNAL.PONE.0",23,YR,,M,Y,101,KG,20200103,,HP,TH,TH,EFAVIRENZ.,Alanine aminotransferase increased;Aspartate aminotransferase increased;Hepatic fibrosis;Hepatic function abnormal;Hepatic steatosis;Nonalcoholic fatty liver disease,172287451,OT,,,,,,,,,172287451,1,Perinatal HIV infection
17237436,172374361,1,I,,20191223,20200106,20200106,EXP,,CA-JNJFOC-20191243323,JOHNSON AND JOHNSON,,52,YR,,M,Y,,,20200106,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,172374361,OT,,,,,,,,,172374361,1,HIV infection
17244551,172445512,2,F,,20200106,20200107,20200110,EXP,,CA-GILEAD-2020-0445490,GILEAD,,52,YR,A,M,Y,,,20200110,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,172445512,OT,,,,,,,,,172445512,1,HIV infection
17249734,172497341,1,I,20190425,20200102,20200109,20200109,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-000815,BRISTOL MYERS SQUIBB,,37,YR,,F,Y,,,20200109,,HP,GB,GB,EFAVIRENZ.,Maternal exposure during pregnancy;Normal newborn;Twin pregnancy;Vanishing twin syndrome,172497341,OT,,,,,,,,,172497341,1,HIV infection
17250665,172506653,3,F,,20200106,20200109,20200211,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020003324,VIIV,,52,YR,,M,Y,,,20200211,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,172506653,OT,,,,,,,,,172506653,1,HIV infection
17250675,172506753,3,F,,20200106,20200109,20200211,EXP,,CA-GLAXOSMITHKLINE-CA2020003324,GLAXOSMITHKLINE,,52,YR,,M,Y,,,20200211,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,172506753,OT,,,,,,,,,172506753,1,HIV infection
17250797,172507971,1,I,,20180305,20200109,20200109,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2018GSK038176,VIIV,,45,YR,,M,Y,,,20200109,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,172507971,OT,,,,,,,,,172507971,1,HIV infection
17250798,172507981,1,I,,20180305,20200109,20200109,EXP,,CA-GLAXOSMITHKLINE-CA2018GSK038176,GLAXOSMITHKLINE,,45,YR,,M,Y,,,20200109,,HP,CA,CA,EFAVIRENZ.,Multiple-drug resistance,172507981,OT,,,,,,,,,172507981,1,HIV infection
17256109,172561091,1,I,,20200103,20200110,20200110,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020GSK004894,VIIV,,37,YR,,F,Y,,,20200110,,CN,US,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Foetal death,172561091,OT,,,,,,,,,172561091,1,HIV infection
17256115,172561151,1,I,,20200103,20200110,20200110,EXP,,GB-GLAXOSMITHKLINE-GB2020GSK004894,GLAXOSMITHKLINE,,37,YR,,F,Y,,,20200110,,CN,US,GB,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy;Foetal death,172561151,OT,,,,,,,,,172561151,1,HIV infection
17257415,172574151,1,I,,20200106,20200110,20200110,EXP,,IN-MYLANLABS-2020M1003974,MYLAN,"DAVE M, SR L, PATIDAR M, BAPAT P, JITERWAL M, YADAV K, ET AL. HAART INDUCED GYNAECOMASTIA. J-ASSOC-PHYSICIANS-INDIA 2019;67(12):82-83.",42,YR,,M,Y,65,KG,20200110,,MD,IN,IN,EFAVIRENZ.,Gynaecomastia,172574151,HO,,,,,,,,,172574151,1,HIV infection
17257723,172577233,3,F,,20200128,20200110,20200203,EXP,,PT-MYLANLABS-2020M1002389,MYLAN,"CERTAL M, CUNHA RG, MOUTINHO A, TAVARES S, GUIMAR?ES F, MARQUES PV.. HIPOPITUITARISMO EM DOENTE COM CO-INFEC??O PELO V?RUS DA IMUNODEFICI?NCIA HUMANA (VIH) TIPO 1 E HEPATITE C (VHC) CR?NICA.EPOSTER:DOEN?AS END?CRINAS E METAB?LICAS.. CONGRESSO NACIONAL DE MEDICINA INTERNA. 2019;23-26",45,YR,,M,Y,,,20200203,,MD,PT,PT,EFAVIRENZ.,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,172577233,HO,,,172577233,2,2010,,,,172577233,1,HIV infection
17257731,172577311,1,I,,20200106,20200110,20200110,EXP,,PT-MYLANLABS-2020M1002400,MYLAN,"CERTAL M, CUNHA RG, MOUTINHO A, TAVARES S, GUIMARAES  F, MARQUES  PV ET AL.. HIPOPITUITARISM IN CO-INFECTED SICKNESS BY IMMUNODEFICIENCY VIRUS HUMAN (HIV) TYPE 1 AND CHRONIC HEPATITIS C (HCV).. 25 CONGRESSO NACIONAL DE MEDICINA INTERNA:ENDOCRINE AND METABOLIC DISEASES-E-POS. 2019",,,A,M,Y,,,20200110,,HP,PT,PT,EFAVIRENZ.,Alopecia;Breast pain;Diabetes insipidus;Erectile dysfunction;Gynaecomastia;Hypogonadism;Hypopituitarism;Libido decreased;Polydipsia;Weight increased,172577311,OT,,,,,,,,,172577311,1,HIV infection
17258676,172586761,1,I,201906,20200106,20200110,20200110,EXP,,FR-MYLANLABS-2020M1002669,MYLAN,,,,,,Y,,,20200110,,CN,FR,FR,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Drug ineffective;Viral load increased,172586761,OT,,,172586761,1,2009,,,,172586761,1,Product used for unknown indication
17261505,172615052,2,F,201202,20200317,20200113,20200324,PER,,US-GILEAD-2020-0446114,GILEAD,,43,YR,A,M,Y,81.18,KG,20200324,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Dehydration;Diarrhoea;Economic problem;Emotional distress;Fanconi syndrome acquired;Pain;Pancreatitis;Vomiting,172615052,HO,,,172615052,1,201110,20120309,,,172615052,1,HIV infection
17262061,172620612,2,F,20150115,20200317,20200113,20200324,EXP,,US-GILEAD-2020-0446121,GILEAD,,51,YR,A,M,Y,,,20200324,,CN,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Pain,172620612,OT,,,172620612,1,20070427,20170424,,,172620612,1,HIV infection
17262217,172622171,1,I,,20190623,20200113,20200113,PER,,US-APOTEX-2019AP017663,APOTEX,"HARZKE AJ, DIAZ M, TONG E, BAILLARGEON G, ZEPEDA S, KORANEK A, SANDMANN R.. SUBSTITUTING GENERIC LAMIVUDINE FOR EMTRICITABINE IN VIROLOGICALLY SUPPRESSED HIV-INFECTED PATIENTS. DOI: 10.1177/1078345818792834. JOURNAL OF CORRECTIONAL HEALTH CARE. 2018",,,A,,Y,,,20200113,,HP,US,US,EFAVIRENZ.,Nervous system disorder,,,,,,,,,,,172622171,1,HIV infection
17265362,172653621,1,I,,20200102,20200114,20200114,EXP,,US-AUROBINDO-AUR-APL-2020-002236,AUROBINDO,,24,YR,,M,Y,,,20200114,,HP,US,US,EFAVIRENZ.,Acute myocardial infarction;Coronary artery disease;Electrocardiogram ST segment elevation,172653621,OT,,,,,,,,,172653621,1,Perinatal HIV infection
17268421,172684213,3,F,,20200316,20200114,20200327,EXP,,NG-MYLANLABS-2020M1004305,MYLAN,"ABDULLAHI ZG, SHITTU OS, KOLEDADE AK, MOHAMMED U, MAIKUDI HA, IGASHI JB, ET AL. THE BENEFITS OF A GUIDELINE ON SAFE TERMINATION OF PREGNANCY FOR LEGAL INDICATIONS: AN ILLUSTRATIVE CASE REPORT OF A HYDRANENCEPHALY. AFR-J-REPROD-HEALTH 2019;23(2):148-151.",,,,,Y,,,20200327,,HP,NG,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy,172684213,CA,,,,,,,,,172684213,1,Retroviral infection
17269385,172693851,1,I,,20190717,20200114,20200114,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2019GSK129219,VIIV,"TSENG AL, WONG AYJ, MCLELLAND CJ, WALMSLEY SL.. DRUG INTERACTIONS ARE NOT ALWAYS PREDICTABLE: THE CURIOUS CASE OF VALPROIC ACID AND DOLUTEGRAVIR AND A POSSIBLE EXPLANATION. AIDS. 2019;33(10):1677-1679 DOI: 10.1097/QAD.000",43,YR,,F,Y,,,20200114,,PH,CA,CA,EFAVIRENZ.,Anticonvulsant drug level below therapeutic;Antiviral drug level below therapeutic;Drug interaction;Drug level below therapeutic;Seizure,172693851,OT,,,172693851,1,201810,,,,172693851,1,HIV infection
17269614,172696141,1,I,20191224,,20191224,20191224,DIR,,,FDA-CTU,,67,YR,,M,N,,,20191224,N,,US,US,EFAVIRENZ TAB 600MG,Intentional product use issue,,,,,172696141,1,201801,,,,172696141,1,HIV infection
17271641,172716411,1,I,,20191022,20200115,20200115,EXP,,DK-ALKEM LABORATORIES LIMITED-DK-ALKEM-2019-09143,ALKEM,"MARIE HOUGAARD CHRISTENSEN M, BRUUN HAASTRUP M, OHLENSCHLAEGER T, ESBECH P, ET AL.. INTERACTION POTENTIAL BETWEEN CLARITHROMYCIN AND INDIVIDUAL STATINS - A SYSTEMATIC REVIEW. BASIC CLIN PHARMACOL TOXICOL. 2019;UNK:UNK",34,YR,,M,Y,,,20200115,,HP,DK,DK,EFAVIRENZ.,Drug interaction;Rhabdomyolysis,172716411,OT,,,,,,,,,172716411,1,Product used for unknown indication
17274781,172747811,1,I,,20200109,20200115,20200115,EXP,,IN-STRIDES ARCOLAB LIMITED-2020SP000318,STRIDES,"DAVE M, SR L, PATIDAR M, BAPAT P, JITERWAL M, YADAV K, ET AL.. HAART INDUCED GYNAECOMASTIA.. JOURNAL OF THE ASSOCIATION OF PHYSICIANS OF INDIA. 2019;67(12):82-83",42,YR,,M,Y,,,20200116,,HP,IN,IN,EFAVIRENZ.,Gynaecomastia,172747811,HO,,,,,,,,,172747811,1,HIV infection
17274987,172749871,1,I,20050602,20200103,20200116,20200116,EXP,,ZA-MACLEODS PHARMACEUTICALS US LTD-MAC2020024763,MACLEODS,,,,,,Y,,,20200116,,HP,ZA,ZA,EFAVIRENZ.,Autoimmune haemolytic anaemia;Hypersensitivity,172749871,OT,,,172749871,1,20050510,20050602,,,172749871,1,HIV infection WHO clinical stage III
17281855,172818551,1,I,,20200114,20200117,20200117,EXP,GB-MHRA-EYC 00215719,GB-LUPIN PHARMACEUTICALS INC.-2020-00197,LUPIN,,49,YR,,M,Y,,,20200117,,CN,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172818551,OT,,,,,,,,,172818551,1,HIV infection
17285288,172852884,4,F,2017,20200211,20200117,20200212,EXP,,US-GILEAD-2020-0445178,GILEAD,,60,YR,A,F,Y,,,20200212,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Asthenia;Dyspnoea;Fatigue;Feeling jittery;Groin infection;Hypertension;Intentional dose omission;Internal haemorrhage;Loss of consciousness;Malaise;Nausea;Nervousness;Off label use;Pyrexia;Rash;Stress;Thrombosis,172852884,DS,,,,,,,,,172852884,1,Human T-cell lymphotropic virus type I infection
17286891,172868911,1,I,,20200114,20200120,20200120,EXP,,GB-AUROBINDO-AUR-APL-2020-003203,AUROBINDO,,49,YR,,M,Y,,,20200120,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172868911,OT,,,,,,,,,172868911,1,HIV infection
17288035,172880353,3,F,20191211,20200220,20200120,20200228,EXP,,ZA-VIIV HEALTHCARE LIMITED-ZA2019GSK212578,VIIV,,,,,F,Y,,,20200228,,MD,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,172880353,OT,,,172880353,1,20170508,20191125,,,172880353,1,HIV infection
17288036,172880361,1,I,,20200116,20200120,20200120,EXP,GB-MHRA-EYC 00215719,GB-VIIV HEALTHCARE LIMITED-GB2020008852,VIIV,,49,YR,,M,Y,,,20200120,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172880361,LT,,,,,,,,,172880361,1,HIV infection
17288043,172880431,1,I,,20200116,20200120,20200120,EXP,GB-MHRA-EYC 00215719,GB-GLAXOSMITHKLINE-GB2020008852,GLAXOSMITHKLINE,,49,YR,,M,Y,,,20200120,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172880431,OT,,,,,,,,,172880431,1,HIV infection
17290120,172901201,1,I,,20200115,20200120,20200120,PER,,NVSC2020US011372,NOVARTIS,KELLY SL. TIMELY FORMULARY MANAGEMENT FOR PREVENTING ERRORS RELATED TO ANTIRETROVIRAL DRUGS. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY. 2013;70(12):1014-15,48,YR,,M,Y,,,20200121,,HP,US,US,EFAVIRENZ.,Drug resistance;Product name confusion,,,,,,,,,,,172901201,1,Antiretroviral therapy
17295433,172954331,1,I,,20200115,20200121,20200121,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-003557,BRISTOL MYERS SQUIBB,,49,YR,,M,Y,,,20200121,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,172954331,OT,,,,,,,,,172954331,1,HIV infection
17296315,172963151,1,I,,20191215,20200121,20200121,EXP,,CA-TEVA-2019-CA-1154879,TEVA,,54,YR,,M,Y,,,20200121,,HP,CA,CA,EFAVIRENZ.,Hypertriglyceridaemia,172963151,OT,,,,,,,,,172963151,1,HIV infection
17297051,172970511,1,I,,20190822,20200121,20200121,EXP,,CA-TEVA-2019-CA-1099335,TEVA,,54,YR,,M,Y,83.99,KG,20200121,,MD,CA,CA,TEVA- EFAVIRENZ W/ EMTRICITABINE W/ TENOFOVIR,Abnormal dreams;Dizziness;Fatigue;Insomnia;Malaise;Nausea,172970511,OT,,,,,,,,,,,
17297167,172971671,1,I,,20200116,20200121,20200121,EXP,,CA-TEVA-2020-CA-1172080,TEVA,,58,YR,,M,Y,,,20200121,,PH,CA,CA,TEVA EFAVIRENZ/EMTRICITABINE/TENOFOVIR,Bone density decreased;Osteopenia;Pathological fracture,172971671,HO,,,,,,,,,172971671,1,HIV infection
17297168,172971681,1,I,,20200116,20200121,20200121,EXP,,CA-TEVA-2020-CA-1172076,TEVA,,54,YR,,M,Y,46.31,KG,20200121,,PH,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIRDISOPROXIL FUMARATE;TEVAEFAVIRENZ/EMTRICITABINE/TENOFOVIR,Confusional state;Dizziness;Nightmare;Product substitution issue,172971681,OT,,,,,,,,,,,
17297535,172975351,1,I,,20050711,20200122,20200122,EXP,,ES-BRISTOL-MYERS SQUIBB COMPANY-13031737,BRISTOL MYERS SQUIBB,,40,YR,,M,Y,,,20200122,,CN,ES,ES,EFAVIRENZ.,Acute kidney injury;Hepatitis;Hypersensitivity;Leukocyturia;Pneumonitis;Tuberculosis;Tubulointerstitial nephritis,172975351,OT,,,,,,,,,172975351,1,HIV infection
17303704,173037041,1,I,20170508,20200120,20200122,20200122,EXP,,ZA-GILEAD-2020-0447684,GILEAD,,,,,F,Y,,,20200122,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173037041,OT,,,173037041,1,20170508,,,,173037041,1,HIV infection
17305733,173057333,3,F,20191218,20200203,20200123,20200210,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2020GSK008904,VIIV,,29,YR,,F,Y,,,20200210,,MD,UG,UG,EFAVIRENZ.,Abortion spontaneous,173057333,OT,,,173057333,1,20180606,20191105,,,173057333,1,HIV infection
17308135,173081351,1,I,,20200122,20200123,20200123,EXP,,US-GILEAD-2020-0447959,GILEAD,,44,YR,A,M,Y,,,20200123,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Pneumonia,173081351,OT,,,,,,,,,173081351,1,HIV infection
17309113,173091131,1,I,201007,20100921,20200123,20200123,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-15321177,BRISTOL MYERS SQUIBB,,42,YR,,M,Y,60,KG,20200123,,CN,US,US,EFAVIRENZ.,Blood HIV RNA increased;Drug interaction;Drug level below therapeutic,173091131,OT,,,173091131,2,,20100808,,,173091131,1,Acquired immunodeficiency syndrome
17314568,173145681,1,I,,20200116,20200124,20200124,EXP,,MM-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-004940,BRISTOL MYERS SQUIBB,"LIN KS, WIN S, NYEIN PP. DRUG-INDUCED IMMUNE HEMOLYTIC ANEMIA BECAUSE OF EFAVIRENZ: A CASE REPORT. AIDS. 2020;34(2):326-8",50,YR,,F,Y,,,20200124,,HP,MM,MM,EFAVIRENZ.,Haemolytic anaemia,173145681,OT,,,173145681,1,2015,,,,173145681,1,HIV infection
17314757,173147573,3,F,20171213,20200206,20200124,20200211,EXP,,GB-VIIV HEALTHCARE LIMITED-GB2020GSK011990,VIIV,,18,YR,,M,Y,,,20200211,,MD,GB,GB,EFAVIRENZ.,Pneumonia,173147573,HO,,,173147573,1,20170406,20170109,,,173147573,1,HIV infection
17315252,173152521,1,I,20191211,20200120,20200124,20200124,EXP,,ZA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-005583,BRISTOL MYERS SQUIBB,,,,,F,Y,,,20200124,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173152521,OT,,,173152521,1,20191125,,,,173152521,1,HIV infection
17315702,173157021,1,I,,20200113,20200124,20200124,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-002860,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200124,,HP,CA,CA,SUSTIVA,Abnormal dreams;Drug interaction;Erectile dysfunction;Liver injury;Nail disorder;Renal impairment;Skin ulcer;Thirst;Visual acuity reduced,173157021,OT,,,,,,,,,173157021,1,Product used for unknown indication
17324001,173240012,2,F,20191211,20200130,20200127,20200206,EXP,,ZA-AUROBINDO-AUR-APL-2020-004158,AUROBINDO,,,,,F,Y,,,20200206,,MD,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173240012,OT,,,173240012,1,20191125,,,,173240012,1,HIV infection
17325096,173250961,1,I,,20200118,20200127,20200127,EXP,,IT-MYLANLABS-2020M1007860,MYLAN,,51,YR,,M,Y,,,20200127,,CN,IT,IT,SUSTIVA,Osteoporosis,173250961,OT,,,,,,,,,173250961,1,HIV infection
17325998,173259982,2,F,20191211,20200217,20200127,20200224,EXP,,ZA-MYLANLABS-2020M1007885,MYLAN,,,,,F,Y,,,20200224,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173259982,OT,,,173259982,1,20191125,,,,173259982,1,HIV infection
17330571,173305711,1,I,,20200121,20200128,20200128,EXP,,GB-MYLANLABS-2020M1008905,MYLAN,,,,A,M,Y,,,20200128,,MD,GB,GB,EFAVIRENZ.,Body mass index increased;Diabetes mellitus;Glomerular filtration rate decreased;Hypertension;Proteinuria,173305711,OT,,,,,,,,,173305711,1,HIV infection
17334403,173344031,1,I,,20200120,20200128,20200128,EXP,,IT-ROCHE-2530033,ROCHE,"MANCUSO E, LINARI S, SANTAGOSTINO E, BARTOLOZZI D, D^AMBROSIO R, BORGHI M, LAMPERTICO P, PEYVANDI F, CASTAMAN G AND AGHEMO A HIGH RATE OF SUSTAINED VIROLOGICAL RESPONSE WITH DIRECT-ACTING ANTIVIRALS IN HAEMOPHILIACS WITH HCV INFECTION: A MULTICENTER STUDY. LIVER INTERNATIONAL 2019;00:1-7.",,,A,,Y,,,20200128,,MD,IT,IT,EFAVIRENZ.,Anaemia;Death;Hepatic failure,173344031,DE,,,,,,,,,173344031,1,Hepatitis C
17334678,173346781,1,I,,20200121,20200128,20200128,EXP,,IN-ASTELLAS-2020US003005,ASTELLAS,,24,YR,,M,Y,,,20200128,,CN,GB,IN,EFAVIRENZ.,Drug ineffective,173346781,OT,,,,,,,,,173346781,1,Visceral leishmaniasis
17335073,173350733,3,F,,20200319,20200128,20200325,EXP,,BR-VIIV HEALTHCARE LIMITED-BR2020AMR014738,VIIV,,,,,F,Y,72,KG,20200325,,MD,BR,BR,EFAVIRENZ.,Dizziness;Gastrointestinal disorder;Hepatotoxicity;Transaminases abnormal,173350733,OT,,,173350733,5,20190326,20190826,,,173350733,1,HIV infection
17335755,173357551,1,I,,20200121,20200128,20200128,EXP,,ZA-STRIDES ARCOLAB LIMITED-2020SP000630,STRIDES,,,,,F,Y,,,20200128,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173357551,OT,,,173357551,1,20191125,,,,173357551,1,HIV infection
17345483,173454831,1,I,201706,20200128,20200129,20200129,EXP,,US-GILEAD-2020-0448846,GILEAD,,57,YR,A,M,Y,,,20200129,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Aortic bypass;Walking aid user,173454831,HO,,,,,,,,,173454831,1,HIV infection
17345583,173455831,1,I,,20200122,20200129,20200129,EXP,GB-MHRA-EYC 00215719,GB-TEVA-2020-GB-1175512,TEVA,,49,YR,,M,Y,,,20200129,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,173455831,LT,,,,,,,,,173455831,1,HIV infection
17345612,173456121,1,I,,20200126,20200129,20200129,EXP,,CA-TEVA-2020-CA-1176324,TEVA,,54,YR,,M,Y,,,20200129,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,173456121,OT,,,,,,,,,173456121,1,Bipolar disorder
17346788,173467881,1,I,20191211,20200120,20200130,20200130,EXP,,ZA-HETERO-HET2020ZA00068,HETERO,,,,,F,Y,,,20200130,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,173467881,OT,,,173467881,1,20191125,,,,173467881,1,HIV infection
17347799,173477991,1,I,20170821,20200121,20200130,20200130,EXP,,MD-MYLANLABS-2020M1010799,MYLAN,,25,YR,,M,Y,78,KG,20200130,,MD,MD,MD,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Lip oedema;Pruritus;Rash,173477991,LT,,,173477991,1,20170815,,,,173477991,1,HIV infection
17347802,173478021,1,I,20171109,20200121,20200130,20200130,EXP,,MD-MYLANLABS-2020M1010804,MYLAN,,38,YR,,M,Y,98,KG,20200130,,MD,MD,MD,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Pruritus;Pyrexia;Rash,173478021,LT,,,173478021,1,20171107,,,,173478021,1,HIV infection
17347841,173478411,1,I,20171004,20200121,20200130,20200130,EXP,,MD-MYLANLABS-2020M1010803,MYLAN,,35,YR,,F,Y,97,KG,20200130,,MD,MD,MD,"EFAVIRENZ,EMTRICITABINE,TENOFOVIR MYLAN",Dyspnoea;Eyelid oedema;Lip oedema;Pruritus,173478411,LT,,,173478411,1,20171003,20171004,,,173478411,1,HIV infection
17349384,173493841,1,I,,20200125,20200130,20200130,EXP,,GB-MYLANLABS-2020M1010503,MYLAN,,43,YR,,F,Y,,,20200130,,CN,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173493841,OT,,,173493841,1,20171006,,,,173493841,1,HIV infection
17349388,173493881,1,I,,20200125,20200130,20200130,EXP,,GB-MYLANLABS-2020M1010502,MYLAN,,,,,,Y,,,20200130,,CN,GB,GB,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrops foetalis;Trisomy 18,173493881,OT,,,173493881,2,20171006,,,,173493881,1,Product used for unknown indication
17351390,173513901,1,I,,20200126,20200130,20200130,EXP,,CA-TEVA-2020-CA-1176319,TEVA,,,,,M,Y,,,20200130,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,173513901,DE,,,,,,,,,173513901,1,Product used for unknown indication
17356069,173560691,1,I,,20190905,20200131,20200131,EXP,,CN-GLAXOSMITHKLINE-CN2019GSK161485,GLAXOSMITHKLINE,,,,,,Y,,,20200131,,HP,CN,CN,EFAVIRENZ.,Renal impairment,173560691,OT,,,,,,,,,173560691,1,HIV infection
17358293,173582931,1,I,,20200117,20200201,20200201,EXP,,US-CIPLA (EU) LIMITED-2020US00558,CIPLA,"HSU O, HILL CJ, KIM M, TAN B, O^BRIEN JG.. DECREASED PLASMA EFAVIRENZ CONCENTRATIONS IN A PATIENT RECEIVING RIFABUTIN. AM J HEALTH-SYST PHARM. 2010;67:1611 TO 1614",,,,,Y,,,20200201,,HP,US,US,EFAVIRENZ.,Drug interaction;Drug level below therapeutic;Mycobacterium avium complex infection,173582931,OT,,,,,,,,,173582931,1,HIV infection
17362297,173622971,1,I,,20200129,20200203,20200203,EXP,,BW-MYLANLABS-2020M1011271,MYLAN,,,,,,Y,,,20200203,,HP,BW,BW,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Meningomyelocele,173622971,CA,,,,,,,,,173622971,1,HIV infection
17363179,173631792,2,F,,20200127,20200203,20200211,EXP,,UG-GLAXOSMITHKLINE-UG2020GSK014383,GLAXOSMITHKLINE,"KWIZERA R, KATENDE A, TEU A, APOLOT D, WORODRIA W, KIRENGA BJ ET AL.. ALGORITHM-AIDED DIAGNOSIS OF CHRONIC PULMONARY ASPERGILLOSIS IN LOW- AND MIDDLE-INCOME COUNTRIES BY USE OF A LATERAL FLOW DEVICE. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES. 2020;39 (1):DOI.ORG/10.1007/S10096-019-037",40,YR,,F,Y,,,20200211,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic;Bronchopleural fistula;Bronchopulmonary aspergillosis;HIV infection;Oral candidiasis;Pneumothorax;Virologic failure,173631792,HO,,,,,,,,,173631792,1,HIV infection
17363180,173631802,2,F,,20200127,20200203,20200211,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2020GSK014383,VIIV,"KWIZERA R, KATENDE A, TEU A, APOLOT D, WORODRIA W, KIRENGA BJ ET AL.. ALGORITHM-AIDED DIAGNOSIS OF CHRONIC PULMONARY ASPERGILLOSIS IN LOW- AND MIDDLE-INCOME COUNTRIES BY USE OF A LATERAL FLOW DEVICE. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES. 2020;39 (1):DOI.ORG/10.1007/S10096-019-037",40,YR,,F,Y,,,20200211,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic;Bronchopleural fistula;Bronchopulmonary aspergillosis;HIV infection;Oral candidiasis;Pneumothorax;Virologic failure,173631802,HO,,,,,,,,,173631802,1,HIV infection
17364627,173646271,1,I,,20200121,20200204,20200204,EXP,,ZA-CIPLA LTD.-2020ZA00600,CIPLA,,,,,,Y,,,20200204,,HP,ZA,ZA,EFAVIRENZ.,Abortion spontaneous;Exposure during pregnancy,173646271,OT,,,173646271,1,20191125,,,,173646271,1,HIV infection
17365379,173653791,1,I,,20200128,20200204,20200204,EXP,,BW-HETERO-HET2020BW00114,HETERO,,,,,,Y,,,20200204,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Foetal exposure during pregnancy,173653791,DE,,,,,,,,,173653791,1,HIV infection
17365422,173654221,1,I,20181001,20200128,20200204,20200204,EXP,,BW-HETERO-HET2020BW00113,HETERO,,42,YR,,F,Y,,,20200204,,HP,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Stillbirth,173654221,OT,,,,,,,,,173654221,1,HIV infection
17366054,173660541,1,I,,20200128,20200204,20200204,EXP,,LV-MYLANLABS-2020M1011758,MYLAN,,70,YR,,M,Y,,,20200204,,MD,LV,LV,EFAVIRENZ.,Acute myocardial infarction;Coronary artery disease,173660541,OT,,,173660541,1,201501,,,,173660541,1,HIV infection
17366090,173660901,1,I,,20200128,20200204,20200204,EXP,,UG-MYLANLABS-2020M1011876,MYLAN,,40,YR,,F,Y,,,20200204,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic,173660901,HO,,,,,,,,,173660901,1,HIV infection
17366674,173666741,1,I,,20200129,20200204,20200204,EXP,,BW-MYLANLABS-2020M1013049,MYLAN,,42,YR,,F,Y,,,20200204,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,173666741,OT,,,,,,,,,173666741,1,HIV infection
17371123,173711231,1,I,,20200123,20200205,20200205,EXP,,UG-MACLEODS PHARMACEUTICALS US LTD-MAC2020025069,MACLEODS,,,,,,Y,,,20200205,,HP,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Treatment failure;Treatment noncompliance;VIth nerve disorder,173711231,OT,,,,,,,,,173711231,1,Antiretroviral therapy
17371923,173719231,1,I,,20200126,20200205,20200205,EXP,,UG-HETERO-HET2020UG00098,HETERO,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT.. BMC INFECT DIS. 2020;20(1):68",10,YR,,F,Y,,,20200205,,HP,UG,UG,EFAVIRENZ.,Virologic failure,173719231,OT,,,,,,,,,173719231,1,HIV infection
17375212,173752121,1,I,20181001,20200129,20200205,20200205,EXP,,BW-STRIDES ARCOLAB LIMITED-2020SP000985,STRIDES,,42,YR,,F,Y,,,20200205,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,173752121,OT,,,,,,,,,173752121,1,HIV infection
17375227,173752271,1,I,,20200129,20200205,20200205,EXP,,BW-STRIDES ARCOLAB LIMITED-2020SP000986,STRIDES,,,,,,Y,,,20200205,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele,173752271,CA,,,,,,,,,173752271,1,Product used for unknown indication
17375564,173755641,1,I,,20200203,20200206,20200206,EXP,,IN-GILEAD-2020-0449580,GILEAD,"SALIMI R, BEGUM I, VARMA DM, NANDAKRISHNA B, RAJESH R, VIDYASAGAR S. TENOFOVIR DISOPROXIL FUMARATE-INDUCED DISTAL RENAL TUBULAR ACIDOSIS: A CASE REPORT.. INTERNATIONAL JOURNAL OF STD + AIDS. 2020;0():1-4. DOI:10.1177/0956462419887877",58,YR,A,F,Y,,,20200206,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,173755641,OT,,,,,,,,,173755641,1,HIV infection
17375978,173759782,2,F,,20200210,20200206,20200213,EXP,,BW-AUROBINDO-AUR-APL-2020-005963,AUROBINDO,,,,,,Y,,,20200213,,MD,BW,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,173759782,CA,,,,,,,,,173759782,1,Product used for unknown indication
17375986,173759861,1,I,,20200203,20200206,20200206,EXP,,UG-AUROBINDO-AUR-APL-2020-006516,AUROBINDO,,40,YR,,F,Y,,,20200206,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic,173759861,HO,,,,,,,,,173759861,1,HIV infection
17376247,173762471,1,I,,20200130,20200206,20200206,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK016891,VIIV,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",22,YR,,M,Y,,,20200206,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762471,OT,,,,,,,,,173762471,1,HIV infection
17376248,173762481,1,I,,20200130,20200206,20200206,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK019673,VIIV,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",42,YR,,M,Y,,,20200206,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762481,OT,,,,,,,,,173762481,1,HIV infection
17376294,173762941,1,I,,20200130,20200206,20200206,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK016891,GLAXOSMITHKLINE,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",22,YR,,M,Y,,,20200206,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762941,OT,,,,,,,,,173762941,1,HIV infection
17376298,173762981,1,I,,20200130,20200206,20200206,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK019673,GLAXOSMITHKLINE,"SCHWEM B, DUNGCA NT, AREVALO G, CHING P, PENALOSA-RAMOS C, LIM J ET AL.. RESIDUAL LAMIVUDINE-RESISTANT HEPATITIS B VIRUS DETECTED ON NEXT-GENERATION SEQUENCING OF TREATMENT-EXPERIENCED HIV PATIENTS FAILING ANTIRETROVIRALS. OPEN FORUM INFECTIOUS DISEASES. 2019;6 (SUPPL 2):S189 DOI.ORG/10.1093/OFID/OFZ3",42,YR,,M,Y,,,20200206,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Viral mutation identified;Virologic failure,173762981,OT,,,,,,,,,173762981,1,HIV infection
17376416,173764161,1,I,,20200130,20200206,20200206,EXP,,TH-MYLANLABS-2020M1014071,MYLAN,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS-ONE 2019;14:NO. 12.",21,YR,,M,Y,,,20200206,,HP,TH,TH,EFAVIRENZ.,Nonalcoholic fatty liver disease,173764161,OT,,,,,,,,,173764161,1,HIV infection
17386952,173869521,1,I,,20200127,20200206,20200206,EXP,,UG-GLAXOSMITHKLINE-UG2020GSK014347,GLAXOSMITHKLINE,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N.. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT. BMC INFECTIOUS DISEASES. 2020;20 (1):68, DOI: HTTPS://DOI.ORG/10.11",10,YR,,F,Y,,,20200206,,HP,UG,UG,EFAVIRENZ.,Brain oedema;Generalised tonic-clonic seizure;Headache;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Pyrexia;Treatment noncompliance;VIth nerve paralysis;Virologic failure;Vomiting,173869521,OT,,,,,,,,,173869521,1,HIV infection
17386953,173869531,1,I,,20200127,20200206,20200206,EXP,,UG-VIIV HEALTHCARE LIMITED-UG2020GSK014347,VIIV,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N.. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT. BMC INFECTIOUS DISEASES. 2020;20 (1):68, DOI: HTTPS://DOI.ORG/10.11",10,YR,,F,Y,,,20200206,,HP,UG,UG,EFAVIRENZ.,Brain oedema;Generalised tonic-clonic seizure;Headache;Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Pyrexia;Treatment noncompliance;VIth nerve paralysis;Virologic failure;Vomiting,173869531,OT,,,,,,,,,173869531,1,HIV infection
17387072,173870721,1,I,,20200204,20200206,20200206,PER,,US-GILEAD-2020-0450006,GILEAD,,53,YR,A,M,Y,,,20200206,,CN,US,US,SUSTIVA,Blood creatinine increased;Blood triglycerides increased;Viral load increased,,,,,,,,,,,173870721,1,HIV infection
17388422,173884221,1,I,,20200130,20200207,20200207,EXP,,TH-MYLANLABS-2020M1014072,MYLAN,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY. PLOS-ONE 2019;14:NO. 12.",23,YR,,M,Y,,,20200207,,HP,TH,TH,EFAVIRENZ.,Hepatic fibrosis;Nonalcoholic fatty liver disease,173884221,OT,,,,,,,,,173884221,1,HIV infection
17389306,173893061,1,I,,20200127,20200207,20200207,EXP,,ES-AUROBINDO-AUR-APL-2020-005572,AUROBINDO,,,,A,M,Y,,,20200207,,HP,ES,ES,EFAVIRENZ.,Acute kidney injury;Hepatitis;Hypersensitivity;Leukocyturia;Pneumonitis;Tuberculosis;Tubulointerstitial nephritis,173893061,OT,,,,,,,,,173893061,1,HIV infection
17391520,173915202,2,F,,20200210,20200207,20200219,EXP,,NL-AUROBINDO-AUR-APL-2017-12266,AUROBINDO,,51,YR,,M,Y,,,20200219,,HP,NL,NL,EFAVIRENZ.,Drug interaction;International normalised ratio decreased,173915202,OT,,,173915202,5,200703,200807,,,173915202,1,Thrombosis prophylaxis
17391588,173915881,1,I,,20200203,20200207,20200207,EXP,,GB-MYLANLABS-2020M1013579,MYLAN,,43,YR,,F,Y,,,20200207,,HP,GB,GB,EFAVIRENZ.,Abortion spontaneous;Maternal exposure during pregnancy,173915881,OT,,,,,,,,,173915881,1,Product used for unknown indication
17392205,173922051,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010090,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922051,OT,,,,,,,,,173922051,1,HIV infection
17392207,173922071,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-008788,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922071,OT,,,,,,,,,173922071,1,HIV infection
17392215,173922151,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010102,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922151,OT,,,,,,,,,173922151,1,HIV infection
17392217,173922171,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010103,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922171,OT,,,,,,,,,173922171,1,HIV infection
17392227,173922271,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010100,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922271,OT,,,,,,,,,173922271,1,HIV infection
17392229,173922291,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010101,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922291,OT,,,,,,,,,173922291,1,HIV infection
17392236,173922361,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010097,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922361,OT,,,,,,,,,173922361,1,HIV infection
17392237,173922371,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010098,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922371,OT,,,,,,,,,173922371,1,HIV infection
17392239,173922391,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010099,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922391,OT,,,,,,,,,173922391,1,HIV infection
17392244,173922441,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010094,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922441,OT,,,,,,,,,173922441,1,HIV infection
17392246,173922461,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010096,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922461,OT,,,,,,,,,173922461,1,HIV infection
17392250,173922501,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010095,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922501,OT,,,,,,,,,173922501,1,HIV infection
17392258,173922581,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010093,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922581,OT,,,,,,,,,173922581,1,HIV infection
17392260,173922601,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010092,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922601,OT,,,,,,,,,173922601,1,HIV infection
17392271,173922711,1,I,,20200127,20200207,20200207,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010091,BRISTOL MYERS SQUIBB,"OKPA HO, BISONG EM, ENANG OE, EFFA EE, MONJOK E, ESSIEN EJ. PREDICTORS OF CHRONIC KIDNEY DISEASE AMONG HIV-INFECTED PATIENTS ON HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AT THE UNIVERSITY OF CALABAR TEACHING HOSPITAL, CALABAR, SOUTH-SOUTH NIGERIA. HIV/AIDS - RESEARCH AND PALLIATIVE CARE. 2019;11:61-7",,,A,,Y,,,20200207,,HP,NG,NG,EFAVIRENZ.,Chronic kidney disease,173922711,OT,,,,,,,,,173922711,1,HIV infection
17394728,173947281,1,I,20181001,20200128,20200210,20200210,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-008044,BRISTOL MYERS SQUIBB,,42,YR,,F,Y,,,20200210,,HP,BW,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,173947281,OT,,,,,,,,,173947281,1,HIV infection
17394740,173947401,1,I,,20200128,20200210,20200210,EXP,,BW-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-010640,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200210,,HP,BW,BW,EFAVIRENZ.,Arnold-Chiari malformation;Foetal exposure during pregnancy,173947401,CA,,,,,,,,,173947401,1,Product used for unknown indication
17399860,173998602,2,F,,20200226,20200211,20200305,EXP,,UG-CIPLA LTD.-2020UG01099,CIPLA,"OTTO SBJ, GEORGE PE, MERCEDES R, NABUKEERA-BARUNGI N. CRYPTOCOCCAL MENINGITIS AND IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME IN A PEDIATRIC PATIENT WITH HIV AFTER SWITCHING TO SECOND LINE ANTIRETROVIRAL THERAPY: A CASE REPORT. BMC INFECTIOUS DISEASES. 2020;20 (68):1 TO 5",,,,,Y,,,20200305,,HP,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Treatment noncompliance;Virologic failure,173998602,OT,,,,,,,,,173998602,1,HIV infection
17400438,174004381,1,I,,20200204,20200211,20200211,EXP,,CA-ROCHE-2544734,ROCHE,,,,,M,Y,,,20200211,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,174004381,DE,,,,,,,,,174004381,1,Product used for unknown indication
17400753,174007531,1,I,201310,20200207,20200211,20200211,EXP,GB-EMA-DD-20200205-SHUKLA_V-145820,GB-ACCORD-172205,ACCORD,,39,YR,,M,Y,,,20200211,,CN,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia,174007531,OT,,,174007531,2,200308,200311,,,174007531,1,Bone marrow conditioning regimen
17402682,174026821,1,I,,20200128,20200211,20200211,EXP,,BW-VIIV HEALTHCARE LIMITED-BW2020GSK022110,VIIV,"AJIBOLA G, ROWLEY C, MARUAPULA D, LEIDNER J, BENNETT K, POWIS K ET AL.. DRUG RESISTANCE AFTER CESSATION OF EFAVIRENZ-BASED ANTIRETROVIRAL TREATMENT STARTED IN PREGNANCY. AFR J HIV MED. 2020;21(1):A1023, DOI.ORG/10.4102/SAJHIVM",,,,,Y,,,20200211,,MD,BW,BW,EFAVIRENZ.,Exposure during pregnancy;Live birth;Pathogen resistance;Viral mutation identified,174026821,OT,,,,,,,,,174026821,1,HIV infection
17402737,174027371,1,I,,20200205,20200211,20200211,EXP,,DE-MYLANLABS-2020M1014542,MYLAN,,42,YR,,M,Y,,,20200211,,HP,NG,DE,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174027371,OT,,,,,,,,,174027371,1,HIV infection
17405818,174058181,1,I,,20190425,20200212,20200212,PER,,US-AUROBINDO-AUR-APL-2019-024686,AUROBINDO,,,,,,Y,,,20200212,,MD,US,US,EFAVIRENZ.,Drug hypersensitivity,,,,,,,,,,,174058181,1,Product used for unknown indication
17406123,174061231,1,I,,20200205,20200212,20200212,EXP,,CA-ROCHE-2545776,ROCHE,,,,,M,Y,,,20200212,,CN,CA,CA,EFAVIRENZ.,Depression;Drug interaction,174061231,OT,,,,,,,,,174061231,1,Product used for unknown indication
17406196,174061961,1,I,,20200205,20200212,20200212,EXP,,CA-ROCHE-2545799,ROCHE,,54,YR,,M,Y,,,20200212,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,174061961,OT,,,,,,,,,174061961,1,Bipolar disorder
17406222,174062221,1,I,,20200205,20200212,20200212,EXP,,CA-ROCHE-2545823,ROCHE,,54,YR,,M,Y,,,20200212,,CN,CA,CA,SUSTIVA,Depression;Drug interaction,174062221,OT,,,,,,,,,174062221,1,Product used for unknown indication
17406334,174063341,1,I,,20200205,20200212,20200212,EXP,,CA-ROCHE-2545803,ROCHE,,54,YR,,M,Y,,,20200212,,HP,CA,CA,SUSTIVA,Depression;Drug interaction;Loss of personal independence in daily activities,174063341,OT,,,,,,,,,174063341,1,Bipolar disorder
17407158,174071581,1,I,20181001,20200129,20200212,20200212,EXP,,BW-MACLEODS PHARMACEUTICALS US LTD-MAC2020025048,MACLEODS,,,,,,Y,,,20200212,,HP,US,BW,EFAVIRENZ.,Foetal exposure during pregnancy;Hydrocephalus;Meningomyelocele;Stillbirth,174071581,OT,,,,,,,,,174071581,1,Product used for unknown indication
17410311,174103111,1,I,,20190905,20200212,20200212,EXP,,CN-VIIV HEALTHCARE LIMITED-CN2019GSK161485,VIIV,,,,,,Y,,,20200212,,HP,CN,CN,EFAVIRENZ.,Renal impairment,174103111,OT,,,,,,,,,174103111,1,HIV infection
17411552,174115521,1,I,,20200129,20200213,20200213,EXP,,BW-MACLEODS PHARMACEUTICALS US LTD-MAC2020025068,MACLEODS,,,,,,Y,,,20200213,,HP,US,BW,EFAVIRENZ.,Maternal exposure during pregnancy;Stillbirth,174115521,OT,,,,,,,,,174115521,1,HIV infection
17412233,174122333,3,F,2015,20200319,20200213,20200327,EXP,,US-GILEAD-2020-0450638,GILEAD,,57,YR,A,M,Y,81.6,KG,20200327,,LW,US,US,SUSTIVA,Anhedonia;Anxiety;Chronic kidney disease;Depression;Economic problem;Emotional distress;Osteopenia;Osteoporosis;Pain;Suicidal ideation,174122333,OT,,,174122333,1,201505,201508,,,174122333,1,HIV infection
17413756,174137562,2,F,,20200204,20200213,20200311,EXP,,JP-GILEAD-2017-0300705,GILEAD,,77,YR,E,F,Y,,,20200311,,MD,JP,JP,EFAVIRENZ.,Cachexia;Metastases to liver;Metastases to lung;Metastases to lymph nodes;Oesophageal carcinoma;Oesophageal squamous cell carcinoma metastatic;Off label use;Pneumonia aspiration;Renal impairment,174137562,OT,,,,,,,,,174137562,1,HIV infection
17415569,174155692,2,F,,20200206,20200213,20200220,EXP,,IN-VIIV HEALTHCARE LIMITED-IN2020GSK022741,VIIV,,10,YR,,M,Y,,,20200220,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury;Cough;Febrile neutropenia;General physical health deterioration;Haemophagocytic lymphohistiocytosis;Hepatic enzyme increased;Hypertriglyceridaemia;Pancytopenia;Pleural effusion;Pneumonia;Pulmonary tuberculosis;Pyrexia;Tachypnoea,174155692,OT,,,174155692,1,201706,,,,174155692,1,HIV infection
17415570,174155702,2,F,,20200206,20200213,20200220,EXP,,IN-GLAXOSMITHKLINE-IN2020GSK022741,GLAXOSMITHKLINE,,10,YR,,M,Y,,,20200220,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury;Cough;Febrile neutropenia;General physical health deterioration;Haemophagocytic lymphohistiocytosis;Hepatic enzyme increased;Hypertriglyceridaemia;Pancytopenia;Pleural effusion;Pneumonia;Pulmonary tuberculosis;Pyrexia;Tachypnoea,174155702,OT,,,174155702,1,201706,,,,174155702,1,HIV infection
17418310,174183102,2,F,201801,20200306,20200213,20200318,EXP,,MM-AUROBINDO-AUR-APL-2020-007342,AUROBINDO,,39,YR,,F,Y,,,20200318,,HP,MM,MM,EFAVIRENZ.,Asthenia;Autoimmune haemolytic anaemia;Dyspnoea exertional;Pallor;Tachycardia,174183102,HO,,,174183102,1,2015,,,,174183102,1,HIV infection
17422452,174224522,2,F,,20200201,20200215,20200215,EXP,,IN-HETERO-HET2020IN00088,HETERO,"RAJESH R, SALIMI R, BEGUM I1 VARMA DM, NANDAKRISHNA B, VIDYASAGAR S.. TENOFOVIR DISOPROXIL FUMARATE-INDUCED DISTAL RENAL TUBULAR ACIDOSIS: A CASE REPORT. INTERNATIONAL JOURNAL OF STD + AIDS. 2020;1-4",58,YR,,F,Y,,,20200215,,HP,IN,IN,EFAVIRENZ.,Oropharyngeal candidiasis;Renal tubular acidosis,174224522,OT,,,,,,,,,174224522,1,HIV infection
17423538,174235381,1,I,,20200204,20200217,20200217,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-009805,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200217,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,174235381,OT,,,,,,,,,174235381,1,HIV infection
17423840,174238401,1,I,,20200206,20200217,20200217,EXP,,CA-AUROBINDO-AUR-APL-2020-007477,AUROBINDO,,,,,,Y,,,20200217,,HP,CA,CA,EFAVIRENZ.,Hypertriglyceridaemia,174238401,OT,,,,,,,,,174238401,1,HIV infection
17424136,174241362,2,F,20100506,20200318,20200217,20200325,EXP,,US-GILEAD-2020-0450654,GILEAD,,48,YR,A,M,Y,,,20200325,,CN,US,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Hip arthroplasty;Pain,174241362,HO,,,174241362,1,20070109,200704,,,174241362,1,HIV infection
17425042,174250421,1,I,,20200203,20200218,20200218,EXP,,UG-HETERO-HET2020UG00146,HETERO,"KWIZERA R, KATENDE A, TEU A, APOLOT D, WORODRIA W, KIRENGA BJ, ET AL.. ALGORITHM-AIDED DIAGNOSIS OF CHRONIC PULMONARY ASPERGILLOSIS IN LOW- AND MIDDLE-INCOME COUNTRIES BY USE OF A LATERAL FLOW DEVICE. EUR-J-CLIN-MICROBIOL-INFECT-DIS. 2020;39(1):1-3",40,YR,,F,Y,,,20200218,,HP,UG,UG,EFAVIRENZ.,Anaemia macrocytic;Treatment failure,174250421,HO,,,,,,,,,174250421,1,HIV infection
17426359,174263591,1,I,,20200207,20200217,20200217,EXP,,IN-SA-2020SA034426,SANOFI AVENTIS,,10,YR,C,M,Y,,,20200217,,HP,IN,IN,EFAVIRENZ.,Febrile neutropenia;Hepatic enzyme increased;Pancytopenia,174263591,OT,,,174263591,1,2018,,,,174263591,1,Pulmonary tuberculosis
17427792,174277921,1,I,,20200210,20200218,20200218,EXP,,NVSC2020CH038861,NOVARTIS,,46,YR,,F,Y,,,20200218,,HP,CH,CH,EFAVIRENZ.,Exposure during pregnancy;Premature delivery,174277921,OT,,,,,,,,,174277921,1,Premature labour
17428104,174281041,1,I,,20200210,20200217,20200217,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK027685,VIIV,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174281041,OT,,,,,,,,,174281041,1,HIV infection
17428105,174281051,1,I,,20200210,20200217,20200217,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK027685,GLAXOSMITHKLINE,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174281051,OT,,,,,,,,,174281051,1,HIV infection
17428229,174282291,1,I,,20200210,20200217,20200217,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK027686,VIIV,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174282291,OT,,,,,,,,,174282291,1,HIV infection
17428233,174282331,1,I,,20200210,20200217,20200217,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK027686,GLAXOSMITHKLINE,"ONWUAMAH CK, OKPOKWU J, AUDU R, IMADE G, MELONI ST, OKWURAIWE A ET AL.. LOW LEVELS OF HIV-1 DRUG RESISTANCE MUTATIONS IN PATIENTS WHO ACHIEVED VIRAL RE-SUPPRESSION WITHOUT REGIMEN SWITCH: A RETROSPECTIVE STUDY. BMC MICROBIOLOGY. 2020;20 (1):DOI.ORG/10.1186/S12866-020-170",,,A,,Y,,,20200217,,HP,NG,NG,EFAVIRENZ.,Pathogen resistance;Viral mutation identified,174282331,OT,,,,,,,,,174282331,1,HIV infection
17433146,174331461,1,I,,20200211,20200219,20200219,EXP,,CA-AUROBINDO-AUR-APL-2020-008623,AUROBINDO,,,,,M,Y,,,20200219,,HP,CA,CA,SUSTIVA,Depression;Drug interaction,174331461,OT,,,,,,,,,174331461,1,Product used for unknown indication
17437782,174377821,1,I,201310,20200210,20200219,20200219,EXP,,GB-BAXTER-2020BAX003049,BAXTER,"KANELLOPOULOS A, KAPAROU M, XENOU E, PANEESHA S, KISHORE B, LOVELL R, HOLDER K, SUHR J, BAKER L, RYAN L, NIKOLOUSIS E. GRAFT-VERSUS-LEUKAEMIA EFFECT POST FLUDARABINE, MELPHALAN AND ALEMTUZUMAB REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANT IN HIV-INFECTED PATIENT WITH ACUTE MYELOID LEUKAEMIA. BONE MARROW TRANSPLANTATION. 2018;53(12):1518-1521.",39,YR,,M,Y,,,20200219,,HP,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia;Product use in unapproved indication,174377821,HO,,,174377821,1,200308,200311,,,174377821,1,B precursor type acute leukaemia
17438180,174381801,1,I,,20200205,20200220,20200220,EXP,,IN-MACLEODS PHARMACEUTICALS US LTD-MAC2020025190,MACLEODS,,,,,,Y,,,20200220,,HP,IN,IN,Efavirenz (EFV),Drug hypersensitivity;Oropharyngeal candidiasis;Renal tubular acidosis,174381801,HO,,,,,,,,,174381801,1,HIV infection
17438344,174383441,1,I,,20200217,20200220,20200220,EXP,,PH-AUROBINDO-AUR-APL-2020-009707,AUROBINDO,,22,YR,,M,Y,,,20200220,,HP,PH,PH,EFAVIRENZ+LAMIVUDINE +TENOFOVIR DISOPROXIL FUMARATE,Drug resistance,174383441,OT,,,,,,,,,174383441,1,HIV infection
17439483,174394831,1,I,,20200214,20200220,20200220,EXP,,CN-STRIDES ARCOLAB LIMITED-2020SP001561,STRIDES,,,,,,Y,,,20200220,,HP,CN,CN,EFAVIRENZ.,Blood cholesterol abnormal,174394831,OT,,,,,,,,,174394831,1,HIV infection
17440556,174405561,1,I,2012,20130214,20200220,20200220,EXP,,BR-GLAXOSMITHKLINE-A1012284A,GLAXOSMITHKLINE,,0,YR,,F,Y,2.9,KG,20200220,,CN,US,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,174405561,CA,,,174405561,1,20121128,20121128,,,174405561,1,HIV infection
17440919,174409191,1,I,,20200212,20200220,20200220,EXP,,MM-MYLANLABS-2020M1018492,MYLAN,,50,YR,,F,Y,,,20200220,,HP,MM,MM,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Haemolytic anaemia,174409191,HO,,,,,,,,,174409191,1,HIV infection
17441006,174410061,1,I,,20200213,20200220,20200220,EXP,,IN-MYLANLABS-2020M1019576,MYLAN,,10,YR,,M,Y,,,20200220,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury,174410061,HO,,,174410061,2,201706,,,,174410061,1,HIV infection
17442817,174428171,1,I,,20200210,20200221,20200221,EXP,,IN-CIPLA LTD.-2020IN01149,CIPLA,,,,,,Y,,,20200221,,HP,IN,IN,EFAVIRENZ.,Renal tubular acidosis,174428171,OT,,,,,,,,,174428171,1,HIV infection
17443664,174436641,1,I,,20200210,20200221,20200221,EXP,,TH-HETERO-HET2020TH00184,HETERO,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY.. PLOS-ONE. 2019;14 (12):1-16",23,YR,,M,Y,36,KG,20200221,,HP,TH,TH,EFAVIRENZ.,Hepatic fibrosis;Nonalcoholic fatty liver disease,174436641,OT,,,,,,,,,174436641,1,HIV infection
17443992,174439921,1,I,,20200210,20200221,20200221,EXP,,TH-HETERO-HET2020TH00186,HETERO,"SUDJARITRUK T, BUNUPURADAH T, AURPIBUL L, KOSALARAKSA P, KURNIATI N, SOPHONPHAN J, ET AL.. NONALCOHOLIC FATTY LIVER DISEASE AND HEPATIC FIBROSIS AMONG PERINATALLY HIV-MONOINFECTED ASIAN ADOLESCENTS RECEIVING ANTIRETROVIRAL THERAPY.. PLOS-ONE. 2019;14(12):1-16",21,YR,,M,Y,31,KG,20200221,,HP,TH,TH,EFAVIRENZ.,Nonalcoholic fatty liver disease,174439921,OT,,,,,,,,,174439921,1,HIV infection
17445442,174454421,1,I,,20200211,20200221,20200221,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-012332,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200221,,PH,GB,GB,SUSTIVA,Neoplasm malignant,174454421,OT,,,,,,,,,174454421,1,HIV infection
17446332,174463323,3,F,,20200226,20200221,20200227,EXP,,CA-PFIZER INC-2004047160,PFIZER,,,,,M,Y,3.45,KG,20200227,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Brachycephaly;Conductive deafness;Congenital eyelid malformation;Congenital musculoskeletal anomaly;Congenital nose malformation;Craniosynostosis;Deafness bilateral;Deformity of orbit;Drug withdrawal syndrome neonatal;Dysmorphism;Eyelid ptosis congenital;Foetal exposure during pregnancy;Hydronephrosis;Hypertelorism of orbit;Neonatal seizure;Radioulnar synostosis;Skull malformation;Syndactyly;Synostosis,174463323,CA,,,,,,,,,174463323,1,Vulvovaginal candidiasis
17450269,174502691,1,I,2018,20200213,20200224,20200224,EXP,,IN-AXELLIA-003000,XELLIA PHARMACEUTICALS,"BAJRACHARYA P, KALRA S, JAIN G, SOOD A. UNUSUALLY COMPLICATED COURSE OF A COMMON DISEASE: CHALLENGES IN MANAGING PEDIATRIC HIV. MEDICAL JOURNAL ARMED FORCES INDIA. 2020;76(1):118-119.",10,YR,C,M,Y,,,20200224,,MD,IN,IN,EFAVIRENZ.,Acute kidney injury;Nephropathy toxic,174502691,HO,,,174502691,1,2018,2018,,,174502691,1,Antibiotic therapy
17452252,174522521,1,I,,20200221,20200224,20200224,EXP,,US-GILEAD-2020-0452212,GILEAD,,,,A,M,Y,,,20200224,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Bipolar disorder;Post-traumatic stress disorder,174522521,OT,,,,,,,,,174522521,1,HIV infection
17452307,174523072,2,F,2001,20200319,20200224,20200325,EXP,,ES-MYLANLABS-2020M1018675,MYLAN,,,,A,M,Y,,,20200325,,HP,CL,ES,EFAVIRENZ.,Neurotoxicity,174523072,OT,,,174523072,1,2001,2001,,,174523072,1,HIV infection
17457587,174575871,1,I,,20200218,20200225,20200225,EXP,,ES-MYLANLABS-2020M1019289,MYLAN,"ANGEL-MORENO-MAROTO A, SUAREZ-CASTELLANO L, HERNANDEZ-CABRERA M, PEREZ-ARELLANO J-L.. SEVERE EFAVIRENZ-INDUCED HYPERSENSITIVITY SYNDROME (NOT-DRESS) WITH ACUTE RENAL FAILURE.. J INFECT.. 2006;52(2):E39-40",,,A,,Y,,,20200225,,HP,ES,ES,EFAVIRENZ.,Acute kidney injury;Drug reaction with eosinophilia and systemic symptoms,174575871,OT,,,,,,,,,174575871,1,HIV infection
17463889,174638891,1,I,,20200213,20200226,20200226,EXP,,IN-MYLANLABS-2020M1019539,MYLAN,"GUPTA A, VERMA A, KASHYAP M, GAUTAM P. ART IN PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV. J-OBSTET-GYNECOL-INDIA 2020;70(1):18-22.",,,N,,Y,,,20200226,,MD,IN,IN,"EFAVIRENZ,LAMIVUDINE,TENOFOVIR MYLAN",Drug ineffective;Foetal exposure during pregnancy,174638891,OT,,,,,,,,,174638891,1,Prophylaxis against HIV infection
17463890,174638901,1,I,,20200213,20200226,20200226,EXP,,IN-MYLANLABS-2020M1019538,MYLAN,"GUPTA A, VERMA A, KASHYAP M, GAUTAM P. ART IN PREVENTION OF MOTHER-TO-CHILD TRANSMISSION OF HIV. J-OBSTET-GYNECOL-INDIA 2020;70(1):18-22.",,,N,,Y,,,20200226,,MD,IN,IN,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Drug ineffective;Foetal exposure during pregnancy,174638901,OT,,,,,,,,,174638901,1,Prophylaxis against HIV infection
17465175,174651751,1,I,,20200220,20200226,20200226,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-010577",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200227,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Progressive external ophthalmoplegia,174651751,OT,,,,,,,,,174651751,1,HIV infection
17466150,174661501,1,I,,20200220,20200227,20200227,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-010629",BOEHRINGER INGELHEIM,,,,,,Y,,,20200227,,MD,CA,CA,MYLAN EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Atrial septal defect;Ventricular septal defect,174661501,OT,,,,,,,,,174661501,1,HIV infection
17466467,174664671,1,I,201310,20200212,20200227,20200227,EXP,,GB-SA-2020SA037796,SANOFI AVENTIS,"KANELLOPOULOS A, KAPAROU M, XENOU E, PANEESHA S, KISHORE B, LOVELL R ET AL. GRAFT-VERSUS-LEUKAEMIA EFFECT POST FLUDARABINE, MELPHALAN AND ALEMTUZUMAB REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTAT IN HIV-INFECTED PATIENT WITH ACUTE MYELOID LEUKAEMIA.. BONE MARROW TRANSPLANTATION.. 2018;53(12):1518-21",39,YR,A,M,Y,,,20200227,,HP,GB,GB,EFAVIRENZ.,Acute myeloid leukaemia;Off label use;Pancytopenia;Pneumonia,174664671,HO,,,174664671,1,200308,200311,,,174664671,1,B precursor type acute leukaemia
17467168,174671681,1,I,,20200220,20200227,20200227,EXP,,CA-VIIV HEALTHCARE LIMITED-CA2020AMR031068,VIIV,,,,,,Y,,,20200227,,HP,CA,CA,EFAVIRENZ.,Acute kidney injury;Alanine aminotransferase increased;Anaemia;Aspartate aminotransferase increased;Blood bilirubin increased;Cerebral ischaemia;Cystitis noninfective;Drug interaction;Febrile neutropenia;Haematuria;Infection;Myalgia;Pulmonary embolism;Seizure;Thrombosis;Tumour lysis syndrome;Vomiting,174671681,OT,,,,,,,,,174671681,1,HIV infection
17469838,174698381,1,I,,20200220,20200227,20200227,EXP,,"CA-B.I. PHARMACEUTICALS,INC./RIDGEFIELD-2020-BI-010587",BOEHRINGER INGELHEIM,,52,YR,,M,Y,,,20200227,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,174698381,OT,,,,,,,,,174698381,1,HIV infection
17484740,174847401,1,I,,20200225,20200302,20200302,EXP,GB-MHRA-EYC 00215719,GB-MYLANLABS-2020M1021957,MYLAN,,49,YR,,M,Y,,,20200302,,PH,GB,GB,EFAVIRENZ.,Acute myocardial infarction;Left ventricular dysfunction,174847401,LT,,,,,,,,,174847401,1,HIV infection
17486133,174861332,2,F,,20200303,20200303,20200316,EXP,,BR-MACLEODS PHARMACEUTICALS US LTD-MAC2020025401,MACLEODS,,,,,,Y,,,20200316,,HP,US,BR,Lamivudine+ Efavirenz + Tenofovir,Foetal exposure during pregnancy;Talipes,174861332,OT,,,174861332,1,20150302,,,,174861332,1,Product used for unknown indication
17488956,174889561,1,I,,20200226,20200303,20200303,EXP,,US-GILEAD-2020-0452968,GILEAD,JOHNSON JE. TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION WITH SIMEPREVIR AND SOFOSBUVIR IN A PATIENT COINFECTED WITH HIV AND CHRONIC KIDNEY DISEASE: A CASE REPORT. 2019 MIDYEAR CLINICAL MEETING OF THE AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACIS. 2019;UNK:UNK,,,,M,Y,,,20200303,,HP,US,US,EFAVIRENZ.,Blood creatinine increased;Glomerular filtration rate decreased;Product dose omission,174889561,OT,,,,,,,,,174889561,1,Chronic hepatitis C
17489680,174896801,1,I,2017,20200225,20200303,20200303,EXP,,PT-GILEAD-2020-0452706,GILEAD,,45,YR,A,M,Y,,,20200303,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure acute;Dyslipidaemia;Headache;Insomnia;Renal impairment,174896801,OT,,,174896801,1,2011,2017,,,174896801,1,HIV infection
17497427,174974271,1,I,20180301,20200303,20200304,20200304,EXP,,ZA-GILEAD-2020-0453451,GILEAD,,,,,F,Y,,,20200304,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,174974271,OT,,,174974271,1,20170625,,,,174974271,1,HIV infection
17497566,174975661,1,I,20170918,20200303,20200304,20200304,EXP,,ZA-GILEAD-2020-0453453,GILEAD,,27,YR,A,F,Y,,,20200304,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,174975661,OT,,,174975661,1,20170821,,,,174975661,1,HIV infection
17498989,174989891,1,I,,20200228,20200305,20200305,PER,,US-HETERO-HET2020US00285,HETERO,,,,,M,Y,,,20200305,,CN,US,US,EFAVIRENZ.,Insomnia,,,,,,,,,,,174989891,1,Product used for unknown indication
17500280,175002801,1,I,,20200301,20200305,20200305,PER,,NVSC2020US060958,NOVARTIS,,33,YR,,M,Y,70.3,KG,20200305,,HP,US,US,EFAVIRENZ.,BK virus infection;Product use in unapproved indication;Renal and pancreas transplant rejection,175002801,OT,,,,,,,,,175002801,1,Immunosuppressant drug therapy
17500754,175007542,2,F,,20200301,20200305,20200305,PER,,NVSC2020US060960,NOVARTIS,,32,YR,,M,Y,76.7,KG,20200305,,HP,US,US,EFAVIRENZ.,BK virus infection;Pancreas transplant rejection;Product use in unapproved indication;Squamous cell carcinoma,175007542,OT,,,,,,,,,175007542,1,Immunosuppressant drug therapy
17502703,175027031,1,I,20180523,20200303,20200305,20200305,EXP,,ZA-GILEAD-2020-0453452,GILEAD,,30,YR,A,F,Y,,,20200305,,MD,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,175027031,OT,,,175027031,1,20170830,,,,175027031,1,HIV infection
17504474,175044741,1,I,,20200228,20200305,20200305,EXP,,ES-MYLANLABS-2020M1023391,MYLAN,,,,A,M,Y,,,20200305,,CN,ES,ES,EFAVIRENZ.,Acute kidney injury;Hepatitis;Hypersensitivity;Leukocyturia;Pneumonitis;Tuberculosis;Tubulointerstitial nephritis,175044741,OT,,,,,,,,,175044741,1,HIV infection
17505377,175053771,1,I,,20200224,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01523,CIPLA,,,,,,Y,,,20200306,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175053771,OT,,,,,,,,,175053771,1,HIV infection
17505379,175053791,1,I,,20200224,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01521,CIPLA,,,,,,Y,,,20200306,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175053791,OT,,,,,,,,,175053791,1,HIV infection
17505657,175056571,1,I,,20200224,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01522,CIPLA,,,,,,Y,,,20200306,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175056571,OT,,,,,,,,,175056571,1,HIV infection
17505659,175056591,1,I,,20200224,20200306,20200306,EXP,,CN-CIPLA LTD.-2020CN01525,CIPLA,,,,,,Y,,,20200306,,HP,CN,CN,EFAVIRENZ.,Drug resistance;Treatment failure,175056591,OT,,,,,,,,,175056591,1,HIV infection
17510274,175102741,1,I,201701,20200304,20200306,20200306,EXP,,PT-ABBVIE-20K-130-3308139-00,ABBVIE,UNKNOWN. SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE.. FARMACEUTICO NEWS. 2020;.,45,YR,,M,Y,,,20200306,,HP,COUNTRY NOT SPECIFIED,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,175102741,OT,,,175102741,1,2009,,,,175102741,1,HIV infection
17511755,175117551,1,I,,20200224,20200307,20200307,EXP,,IN-AUROBINDO-AUR-APL-2020-012429,AUROBINDO,,10,YR,,M,Y,,,20200307,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury;Febrile neutropenia;Haemophagocytic lymphohistiocytosis;Hepatic enzyme increased;Pancytopenia;Pyrexia,175117551,OT,,,175117551,3,201706,,,,175117551,1,HIV infection
17511757,175117572,2,F,,20200306,20200307,20200317,EXP,,IN-AUROBINDO-AUR-APL-2020-012663,AUROBINDO,,1,MON,,,Y,,,20200317,,HP,IN,IN,Tenofovir+Lamivudine+Efavirenz 300mg+300mg+600mg,Foetal exposure during pregnancy;HIV test positive,175117572,OT,,,,,,,,,175117572,1,Prophylaxis against HIV infection
17512904,175129042,2,F,,20200306,20200308,20200319,EXP,,IN-AUROBINDO-AUR-APL-2020-012664,AUROBINDO,,12,MON,,,Y,,,20200319,,HP,IN,IN,Tenofovir+Lamivudine+Efavirenz 300mg+300mg+600mg,Congenital HIV infection;Drug ineffective;Foetal exposure during pregnancy,175129042,OT,,,,,,,,,175129042,1,Prophylaxis against HIV infection
17514117,175141171,1,I,,20200224,20200306,20200306,EXP,,IN-HETERO-HET2020IN00251,HETERO,"BAJRACHARYA P, KALRA S, JAIN G, SOOD A. UNUSUALLY COMPLICATED COURSE OF A COMMON DISEASE: CHALLENGES IN MANAGING PEDIATRIC HIV. MED-J-ARMED-FORCES-INDIA. 2020;76(1):118-119",10,YR,,M,Y,,,20200307,,HP,IN,IN,EFAVIRENZ.,Acute kidney injury,175141171,HO,,,,,,,,,175141171,1,Antiretroviral therapy
17516037,175160371,1,I,,20200225,20200309,20200309,EXP,,BR-MYLANLABS-2020M1025758,MYLAN,,,,I,F,Y,2.1,KG,20200309,,HP,BR,BR,EFAVIRENZ/LAMIVUDINE/TENOFOVIR,Foetal exposure during pregnancy;Talipes,175160371,CA,,,175160371,1,20150302,,,,175160371,1,HIV infection
17518009,175180091,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041139,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180091,OT,,,,,,,,,175180091,1,HIV infection
17518056,175180561,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041307,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180561,OT,,,,,,,,,175180561,1,HIV infection
17518060,175180601,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041307,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180601,OT,,,,,,,,,175180601,1,HIV infection
17518098,175180981,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041306,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180981,OT,,,,,,,,,175180981,1,HIV infection
17518099,175180991,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041306,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175180991,OT,,,,,,,,,175180991,1,HIV infection
17518157,175181571,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041267,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175181571,OT,,,,,,,,,175181571,1,HIV infection
17518159,175181591,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041267,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175181591,OT,,,,,,,,,175181591,1,HIV infection
17518213,175182131,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041268,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182131,OT,,,,,,,,,175182131,1,HIV infection
17518218,175182181,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041303,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182181,OT,,,,,,,,,175182181,1,HIV infection
17518219,175182191,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041303,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182191,OT,,,,,,,,,175182191,1,HIV infection
17518220,175182201,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041268,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182201,OT,,,,,,,,,175182201,1,HIV infection
17518262,175182621,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041269,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182621,OT,,,,,,,,,175182621,1,HIV infection
17518263,175182631,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041302,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182631,OT,,,,,,,,,175182631,1,HIV infection
17518264,175182641,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041269,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182641,OT,,,,,,,,,175182641,1,HIV infection
17518265,175182651,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041302,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175182651,OT,,,,,,,,,175182651,1,HIV infection
17518305,175183051,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041300,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175183051,OT,,,,,,,,,175183051,1,HIV infection
17518306,175183061,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041300,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175183061,OT,,,,,,,,,175183061,1,HIV infection
17518466,175184661,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041270,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175184661,OT,,,,,,,,,175184661,1,HIV infection
17518475,175184751,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041270,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175184751,OT,,,,,,,,,175184751,1,HIV infection
17518834,175188341,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041289,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175188341,OT,,,,,,,,,175188341,1,HIV infection
17518836,175188361,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041289,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175188361,OT,,,,,,,,,175188361,1,HIV infection
17519661,175196611,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041271,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175196611,OT,,,,,,,,,175196611,1,HIV infection
17519666,175196661,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041271,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175196661,OT,,,,,,,,,175196661,1,HIV infection
17519703,175197031,1,I,,20200225,20200310,20200310,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041281,VIIV,,,,A,M,Y,,,20200310,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197031,OT,,,,,,,,,175197031,1,HIV infection
17519715,175197151,1,I,,20200225,20200310,20200310,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041281,GLAXOSMITHKLINE,,,,A,M,Y,,,20200310,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197151,OT,,,,,,,,,175197151,1,HIV infection
17519716,175197161,1,I,,20200225,20200310,20200310,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041282,GLAXOSMITHKLINE,,,,A,M,Y,,,20200310,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197161,OT,,,,,,,,,175197161,1,HIV infection
17519720,175197201,1,I,,20200225,20200310,20200310,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041282,VIIV,,,,A,M,Y,,,20200310,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197201,OT,,,,,,,,,175197201,1,HIV infection
17519744,175197441,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041284,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197441,OT,,,,,,,,,175197441,1,HIV infection
17519746,175197461,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041284,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175197461,OT,,,,,,,,,175197461,1,HIV infection
17519976,175199761,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041272,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175199761,OT,,,,,,,,,175199761,1,HIV infection
17519977,175199771,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041272,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175199771,OT,,,,,,,,,175199771,1,HIV infection
17520023,175200231,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041273,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200231,OT,,,,,,,,,175200231,1,HIV infection
17520024,175200241,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041283,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200241,OT,,,,,,,,,175200241,1,HIV infection
17520025,175200251,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041273,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200251,OT,,,,,,,,,175200251,1,HIV infection
17520026,175200261,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041283,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175200261,OT,,,,,,,,,175200261,1,HIV infection
17520174,175201741,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041274,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175201741,OT,,,,,,,,,175201741,1,HIV infection
17520176,175201761,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041274,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175201761,OT,,,,,,,,,175201761,1,HIV infection
17520226,175202261,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041275,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175202261,OT,,,,,,,,,175202261,1,HIV infection
17520229,175202291,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041275,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175202291,OT,,,,,,,,,175202291,1,HIV infection
17520344,175203441,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041276,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203441,OT,,,,,,,,,175203441,1,HIV infection
17520346,175203461,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041276,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203461,OT,,,,,,,,,175203461,1,HIV infection
17520359,175203591,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041277,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203591,OT,,,,,,,,,175203591,1,HIV infection
17520361,175203611,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041277,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175203611,OT,,,,,,,,,175203611,1,HIV infection
17520401,175204011,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041278,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175204011,OT,,,,,,,,,175204011,1,HIV infection
17520420,175204201,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041278,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175204201,OT,,,,,,,,,175204201,1,HIV infection
17520444,175204441,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041139,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175204441,OT,,,,,,,,,175204441,1,HIV infection
17520472,175204721,1,I,,20200225,20200309,20200309,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041279,VIIV,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175204721,OT,,,,,,,,,175204721,1,HIV infection
17520473,175204731,1,I,,20200225,20200309,20200309,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041279,GLAXOSMITHKLINE,,,,A,M,Y,,,20200309,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175204731,OT,,,,,,,,,175204731,1,HIV infection
17521485,175214851,1,I,20200225,20200302,20200310,20200310,EXP,,GB-MYLANLABS-2020M1024620,MYLAN,,,,,M,Y,,,20200310,,CN,GB,GB,Mylan-Efavirenz / Emtricitabine / Tenofovir Disoproxil Fumarate,Death,175214851,DE,,,,,,,,,175214851,1,Product used for unknown indication
17521893,175218931,1,I,,20200302,20200310,20200310,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-018412,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20200310,,MD,RO,RO,EFAVIRENZ.,Lipodystrophy acquired,175218931,OT,,,,,,,,,175218931,1,HIV infection
17523857,175238571,1,I,,20200302,20200310,20200310,EXP,,RO-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-018430,BRISTOL MYERS SQUIBB,,39,YR,,F,Y,,,20200310,,MD,RO,RO,EFAVIRENZ.,Lipodystrophy acquired,175238571,OT,,,,,,,,,175238571,1,HIV infection
17525586,175255861,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041296,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175255861,OT,,,,,,,,,175255861,1,HIV infection
17525592,175255921,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041309,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175255921,OT,,,,,,,,,175255921,1,HIV infection
17525594,175255941,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041297,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175255941,OT,,,,,,,,,175255941,1,HIV infection
17525595,175255951,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041294,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175255951,OT,,,,,,,,,175255951,1,HIV infection
17525600,175256001,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041296,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256001,OT,,,,,,,,,175256001,1,HIV infection
17525605,175256051,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041309,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256051,OT,,,,,,,,,175256051,1,HIV infection
17525607,175256071,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041297,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Treatment noncompliance;Viral mutation identified;Virologic failure,175256071,OT,,,,,,,,,175256071,1,HIV infection
17525609,175256091,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041294,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256091,OT,,,,,,,,,175256091,1,HIV infection
17525679,175256791,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041317,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256791,OT,,,,,,,,,175256791,1,HIV infection
17525681,175256811,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041315,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256811,OT,,,,,,,,,175256811,1,HIV infection
17525684,175256841,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041311,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256841,OT,,,,,,,,,175256841,1,HIV infection
17525687,175256871,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041313,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256871,OT,,,,,,,,,175256871,1,HIV infection
17525689,175256891,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041295,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256891,OT,,,,,,,,,175256891,1,HIV infection
17525692,175256921,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041316,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256921,OT,,,,,,,,,175256921,1,HIV infection
17525693,175256931,1,I,,20200225,20200311,20200311,EXP,,PH-GLAXOSMITHKLINE-PH2020GSK041314,GLAXOSMITHKLINE,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256931,OT,,,,,,,,,175256931,1,HIV infection
17525698,175256981,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041313,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256981,OT,,,,,,,,,175256981,1,HIV infection
17525699,175256991,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041317,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175256991,OT,,,,,,,,,175256991,1,HIV infection
17525706,175257061,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041314,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257061,OT,,,,,,,,,175257061,1,HIV infection
17525707,175257071,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041311,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257071,OT,,,,,,,,,175257071,1,HIV infection
17525709,175257091,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041315,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257091,OT,,,,,,,,,175257091,1,HIV infection
17525711,175257111,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041295,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257111,OT,,,,,,,,,175257111,1,HIV infection
17525714,175257141,1,I,,20200225,20200311,20200311,EXP,,PH-VIIV HEALTHCARE LIMITED-PH2020GSK041316,VIIV,,,,A,M,Y,,,20200311,,HP,PH,PH,EFAVIRENZ.,Pathogen resistance;Treatment failure;Viral mutation identified;Virologic failure,175257141,OT,,,,,,,,,175257141,1,HIV infection
17529023,175290231,1,I,,20200226,20200312,20200312,EXP,,JP-SUN PHARMACEUTICAL INDUSTRIES LTD-2020RR-240151,RANBAXY,"YOKOTA K, YOTSUMOTO M, MURAMATSU T, SAITO M, KAMIKUBO Y, ICHIKI A, ET AL. LONG-TERM ADMINISTRATION OF PEGYLATED LIPOSOMAL DOXORUBICIN AT ALMOST TWICE THE RECOMMENDED LIFETIME DOSE IN 10 YEARS WITHOUT CARDIOTOXICITY IN A JAPANESE PATIENT WITH HIV-ASSOCIATED KAPOSI SARCOMA. J INFECT CHEMOTHER. 2020;26(2):289-291",42,YR,,M,Y,,,20200312,,HP,JP,JP,EFAVIRENZ.,Condition aggravated;Disease progression,175290231,OT,,,,,,,,,175290231,1,Kaposi's sarcoma
17534028,175340281,1,I,20190201,20200311,20200312,20200312,EXP,,US-GILEAD-2020-0454656,GILEAD,,56,YR,A,M,Y,,,20200312,,CN,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Renal disorder;Renal impairment,175340281,DS,,,,,,,,,175340281,1,HIV infection
17534513,175345131,1,I,2002,20200228,20200312,20200312,EXP,,PT-MYLANLABS-2020M1024443,MYLAN,ABREU R.. A COMBINA??O DTG+3TC NO MUNDO REAL; FARMAC?UTICO NEWS;. JANEIRO-FEVEREIRO. 2020,45,YR,,M,Y,,,20200312,,HP,PT,PT,EFAVIRENZ.,Myalgia;Treatment noncompliance,175345131,HO,,,175345131,2,2002,,,,175345131,1,Antiretroviral therapy
17546253,175462531,1,I,20180311,20200312,20200316,20200316,EXP,,NG-GILEAD-2020-0454807,GILEAD,,43,YR,A,F,Y,,,20200316,,HP,NG,NG,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,175462531,OT,,,,,,,,,175462531,1,Product used for unknown indication
17547388,175473881,1,I,,20200303,20200317,20200317,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-240147,RANBAXY,"GUPTA N, MITTAL A, NISCHAL N. IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME (IRIS)-A DIAGNOSTIC DILEMMA. QJM. 2019;112(12):925-926",38,YR,,M,Y,,,20200317,,HP,IN,IN,EFAVIRENZ.,Acarodermatitis;Immune reconstitution inflammatory syndrome,175473881,OT,,,,,,,,,175473881,1,Antiretroviral therapy
17548253,175482531,1,I,201701,20200304,20200317,20200317,EXP,,PT-AUROBINDO-AUR-APL-2020-012434,AUROBINDO,SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE. FARMACEUTICO NEWS. 2020,45,YR,,M,Y,,,20200317,,HP,PT,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,175482531,HO,,,175482531,1,2011,,,,175482531,1,HIV infection
17548359,175483591,1,I,20180311,20200312,20200317,20200317,EXP,,NG-GILEAD-2020-0454922,GILEAD,,,,,,Y,,,20200317,,HP,NG,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175483591,OT,,,,,,,,,175483591,1,Product used for unknown indication
17549058,175490581,1,I,201701,20200304,20200317,20200317,EXP,,PT-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-019479,BRISTOL MYERS SQUIBB,SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE. FARMACEUTICO NEWS. 2020,45,YR,,M,Y,,,20200317,,HP,PT,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,175490581,HO,,,175490581,1,2011,,,,175490581,1,HIV infection
17549433,175494332,2,F,20180715,20200317,20200317,20200320,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020GSK046275,VIIV,,,,,,Y,,,20200320,,CN,US,NG,EFAVIRENZ.,Congenital hydrocephalus;Death;Foetal exposure during pregnancy;Hydranencephaly,175494332,DE,,,,,,,,,175494332,1,HIV infection
17549495,175494952,2,F,20180715,20200317,20200317,20200320,EXP,,NG-GLAXOSMITHKLINE-NG2020GSK046275,GLAXOSMITHKLINE,,,,,,Y,,,20200320,,CN,US,NG,EFAVIRENZ.,Congenital hydrocephalus;Death;Foetal exposure during pregnancy;Hydranencephaly,175494952,OT,,,,,,,,,175494952,1,HIV infection
17549853,175498532,2,F,201611,20200317,20200317,20200325,EXP,,IN-UCBSA-2020011083,UCB,"KUMARI M, SHAH I, SHETTY NS, KULKARNI S. SUBACUTE SCLEROSING PANENCEPHALITIS (SSPE) IN HIV INFECTED CHILD. THE INDIAN JOURNAL OF PEDIATRICS. 2020;87(3):241",6,YR,,M,Y,,,20200326,,HP,IN,IN,EFAVIRENZ.,Drug ineffective;Measles;Subacute sclerosing panencephalitis;Vaccination failure,175498532,OT,,,175498532,7,,201603,,,175498532,1,Epilepsy
17550710,175507101,1,I,20190719,20200316,20200317,20200317,EXP,,ZA-GILEAD-2020-0455237,GILEAD,,27,YR,A,F,Y,,,20200317,,HP,ZA,ZA,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,175507101,OT,,,175507101,1,20180503,,,,175507101,1,HIV infection
17551291,175512911,1,I,20090619,20190417,20200317,20200317,EXP,,FR-MYLANLABS-2019M1038547,MYLAN,"POUGA L, SANTORO MM, CHARPENTIER C, DI CARLO D, ROMEO I, ARTESE A, ET AL.. NEW RESISTANCE MUTATIONS TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS AT CODON 184 OF HIV-1 REVERSE TRANSCRIPTASE (M184L AND M184T). CHEMICAL BIOLOGY + DRUG DESIGN. 2018",42,YR,,F,Y,,,20200317,,HP,FR,FR,EFAVIRENZ.,Drug resistance;Viral mutation identified,175512911,OT,,,,,,,,,175512911,1,HIV infection
17555412,175554121,1,I,20180701,20200312,20200318,20200318,EXP,,NG-STRIDES ARCOLAB LIMITED-2020SP003733,STRIDES,,,,,,Y,,,20200318,,HP,NG,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy,175554121,CA,,,,,,,,,175554121,1,Product used for unknown indication
17555413,175554131,1,I,20180715,20200312,20200318,20200318,EXP,,NG-STRIDES ARCOLAB LIMITED-2020SP003734,STRIDES,,43,YR,,F,Y,,,20200318,,HP,NG,NG,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,175554131,OT,,,,,,,,,175554131,1,Product used for unknown indication
17559291,175592911,1,I,20180701,20200311,20200319,20200319,EXP,,NG-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-022163,BRISTOL MYERS SQUIBB,,,,,,Y,,,20200319,,HP,NG,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy;Hydranencephaly,175592911,OT,,,,,,,,,175592911,1,Product used for unknown indication
17559418,175594181,1,I,20180311,20200312,20200319,20200319,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020046745,VIIV,,43,YR,,F,Y,,,20200319,,HP,NG,NG,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,175594181,OT,,,,,,,,,175594181,1,Product used for unknown indication
17559419,175594191,1,I,20180311,20200312,20200319,20200319,EXP,,NG-VIIV HEALTHCARE LIMITED-NG2020047178,VIIV,,,,,,Y,,,20200319,,HP,NG,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175594191,CA,,,,,,,,,175594191,1,Product used for unknown indication
17559446,175594461,1,I,20180311,20200312,20200319,20200319,EXP,,NG-GLAXOSMITHKLINE-NG2020046745,GLAXOSMITHKLINE,,43,YR,,F,Y,,,20200319,,HP,NG,NG,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,175594461,OT,,,,,,,,,175594461,1,Product used for unknown indication
17559450,175594501,1,I,20180311,20200312,20200319,20200319,EXP,,NG-GLAXOSMITHKLINE-NG2020047178,GLAXOSMITHKLINE,,,,,,Y,,,20200319,,HP,NG,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175594501,CA,,,,,,,,,175594501,1,Product used for unknown indication
17564646,175646461,1,I,20180701,20200311,20200320,20200320,EXP,,NG-HETERO-HET2020NG00332,HETERO,,,,,,Y,,,20200320,,HP,NG,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175646461,CA,,,,,,,,,175646461,1,HIV infection
17568633,175686331,1,I,,20200312,20200321,20200321,EXP,,NG-MACLEODS PHARMACEUTICALS US LTD-MAC2020025775,MACLEODS,,,,,,Y,,,20200321,,HP,US,NG,EFAVIRENZ.,Foetal exposure during pregnancy;Hydranencephaly,175686331,CA,,,,,,,,,175686331,1,Product used for unknown indication
17568636,175686361,1,I,20180715,20200312,20200321,20200321,EXP,,NG-MACLEODS PHARMACEUTICALS US LTD-MAC2020025774,MACLEODS,,,,,,Y,,,20200321,,HP,US,NG,EFAVIRENZ.,Abortion induced;Maternal exposure during pregnancy,175686361,OT,,,,,,,,,175686361,1,HIV infection
17569210,175692101,1,I,,20200313,20200322,20200322,EXP,,NVSC2020US074543,NOVARTIS,,,,,M,Y,,,20200322,,MD,US,US,SUSTIVA,Blood glucose increased;Decreased appetite;Product use in unapproved indication;Weight decreased,175692101,OT,,,175692101,1,20200214,,,,175692101,1,Eye disorder
17570075,175700752,2,F,,20200324,20200323,20200331,EXP,,NG-AUROBINDO-AUR-APL-2020-013909,AUROBINDO,,,,,F,Y,,,20200401,,MD,NG,NG,EFAVIRENZ.,Congenital hydrocephalus;Foetal exposure during pregnancy,175700752,OT,,,,,,,,,175700752,1,Product used for unknown indication
17571317,175713171,1,I,2018,20200312,20200323,20200323,EXP,,"NG-LANNETT COMPANY, INC.-NG-2020LAN000086",LANNETT,,43,YR,,F,Y,,,20200323,,HP,NG,NG,EFAVIRENZ.,Hydrocephalus;Maternal exposure during pregnancy,175713171,OT,,,,,,,,,175713171,1,Product used for unknown indication
17571617,175716171,1,I,,20200317,20200323,20200323,EXP,,CA-TEVA-2020-CA-1207783,TEVA,,52,YR,,M,Y,,,20200323,,HP,CA,CA,SUSTIVA,Diplopia;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity,175716171,OT,,,,,,,,,175716171,1,HIV infection
17572862,175728622,2,F,20200316,20200320,20200323,20200331,EXP,,GB-MYLANLABS-2020M1032052,MYLAN,,,,,M,Y,,,20200331,,CN,GB,GB,EFAVIRENZ.,Death,175728622,DE,,,,,,,,,175728622,1,Product used for unknown indication
17574294,175742941,1,I,,20200311,20200324,20200324,EXP,,NG-AUROBINDO-AUR-APL-2020-015307,AUROBINDO,,43,YR,,F,Y,,,20200324,,MD,NG,NG,EFAVIRENZ.,Abortion;Exposure during pregnancy,175742941,OT,,,,,,,,,175742941,1,Product used for unknown indication
17578056,175780561,1,I,,20200318,20200324,20200324,EXP,,GB-MYLANLABS-2020M1031604,MYLAN,,,,,M,Y,,,20200324,,CN,GB,GB,EFAVIRENZ MYLAN,Corona virus infection,175780561,OT,,,,,,,,,175780561,1,Product used for unknown indication
17578374,175783741,1,I,,20200316,20200324,20200324,EXP,,US-GILEAD-2020-0455585,GILEAD,"KROWN SE, MOSER CB, MACPHAIL P, MATINING RM, GODFREY C, CARUSO SR, HOSSEINIPOUR MC, SAMANEKA W, NYIRENDA M, BUSAKHALA NW, OKUKU FM,. TREATMENT OF ADVANCED AIDS-ASSOCIATED KAPOSI SARCOMA IN RESOURCE-LIMITED SETTINGS: A THREE-ARM, OPEN-LABEL, RANDOMISED, NON-INFERIORITY TRIAL. LANCET. 2020;UNK:UNK. DOI:HTTPS://DOI.ORG/10.1016/S0140-6736(19)33222-2",,,A,F,Y,,,20200324,,HP,US,US,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Abortion spontaneous;Maternal exposure during pregnancy,175783741,OT,,,,,,,,,175783741,1,HIV infection
17579345,175793451,1,I,,20200126,20200325,20200325,EXP,,BR-GLAXOSMITHKLINE-BR2020AMR014738,GLAXOSMITHKLINE,,,,,F,Y,72,KG,20200325,,MD,BR,BR,EFAVIRENZ.,Dizziness;Gastrointestinal disorder;Hepatotoxicity;Transaminases abnormal,175793451,OT,,,175793451,5,20190326,20190826,,,175793451,1,HIV infection
17579713,175797133,3,F,,20200312,20200325,20200326,EXP,,IN-SUN PHARMACEUTICAL INDUSTRIES LTD-2020R1-241560,RANBAXY,,6,YR,,M,Y,,,20200326,,HP,IN,IN,EFAVIRENZ.,Drop attacks;Fall;Subacute sclerosing panencephalitis,175797133,OT,,,,,,,,,175797133,1,Epilepsy
17581174,175811741,1,I,,,20200325,20200325,DIR,,,FDA-CTU,,,,,M,N,,,20200325,N,,US,US,SUSTIVA,Candida infection;Drug ineffective,,,,,,,,,,,,,
17583328,175833281,1,I,2002,20200316,20200326,20200326,EXP,,PT-AUROBINDO-AUR-APL-2020-015125,AUROBINDO,ABREU R. A COMBINACAO DTG+3TC NO MUNDO REAL; FARMAC?UTICO NEWS. JANEIRO-FEVEREIRO. 2020,45,YR,,M,Y,,,20200326,,HP,PT,PT,EFAVIRENZ.,Myalgia;Treatment noncompliance,175833281,HO,,,175833281,2,2002,,,,175833281,1,Antiretroviral therapy
17583391,175833911,1,I,,20200323,20200326,20200326,EXP,,PE-AUROBINDO-AUR-APL-2020-015876,AUROBINDO,,32,YR,,F,Y,,,20200326,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis,175833911,HO,,,,,,,,,175833911,1,HIV infection
17584138,175841381,1,I,,20200323,20200326,20200326,EXP,,PE-AUROBINDO-AUR-APL-2020-015875,AUROBINDO,,,,,F,Y,,,20200326,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis,175841381,OT,,,,,,,,,175841381,1,HIV infection
17584141,175841411,1,I,,20200312,20200326,20200326,EXP,,NG-CIPLA LTD.-2020NG02102,CIPLA,,,,,,Y,,,20200326,,HP,NG,NG,EFAVIRENZ.,Exposure during pregnancy,175841411,OT,,,,,,,,,175841411,1,HIV infection
17584163,175841631,1,I,,20200316,20200326,20200326,EXP,,PE-MYLANLABS-2020M1032531,MYLAN,"MONTENEGRO-IDROGO JJ, CHIAPPE-GONZALEZ A, VARGAS-GONZALES R, AREVALO J, NAVINCOPA M, TICONA E. DISSEMINATED HISTOPLASMOSIS AND HAEMOPHAGOCYTIC SYNDROME IN HIV PATIENTS: A CASE SERIES IN A PERUVIAN HOSPITAL. REV-IBEROAM-MICOL 2020;37(1):28-33.",33,YR,,F,Y,,,20200326,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis,175841631,HO,,,,,,,,,175841631,1,HIV infection
17585048,175850481,1,I,20200316,20200325,20200326,20200326,EXP,,GB-BRISTOL-MYERS SQUIBB COMPANY-BMS-2020-026067,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200326,,CN,GB,GB,EFAVIRENZ.,Death,175850481,OT,,,,,,,,,175850481,1,Product used for unknown indication
17587129,175871291,1,I,2017,20200319,20200326,20200326,EXP,,PT-MYLANLABS-2020M1031812,MYLAN,,45,YR,,M,Y,,,20200326,,MD,PT,PT,EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE,Cardiac failure acute;Dyslipidaemia;Headache;Insomnia;Renal impairment,175871291,HO,,,175871291,1,2011,2017,,,175871291,1,HIV infection
17587182,175871821,1,I,,20200319,20200326,20200326,EXP,,FR-MYLANLABS-2020M1031822,MYLAN,,,,A,M,Y,60,KG,20200326,,MD,FR,FR,EFAVIRENZ.,Genotype drug resistance test positive;Virologic failure,175871821,OT,,,175871821,1,2006,2007,,,175871821,1,HIV infection
17587478,175874781,1,I,,20200311,20200326,20200326,EXP,,UG-APPCO PHARMA LLC-2082015,APPCO PHARMA,,10,YR,,F,Y,,,20200326,,HP,UG,UG,EFAVIRENZ.,Immune reconstitution inflammatory syndrome;Meningitis cryptococcal;Therapy change;Treatment noncompliance;Virologic failure,175874781,HO,,,,,,,,,175874781,1,HIV infection
17590225,175902251,1,I,,20200316,20200327,20200327,EXP,,PE-MYLANLABS-2020M1032530,MYLAN,"MONTENEGRO-IDROGO JJ, CHIAPPE-GONZALEZ A, VARGAS-GONZALES R, AREVALO J, NAVINCOPA M, TICONA E. DISSEMINATED HISTOPLASMOSIS AND HAEMOPHAGOCYTIC SYNDROME IN HIV PATIENTS: A CASE SERIES IN A PERUVIAN HOSPITAL. REV-IBEROAM-MICOL 2020;37(1):28-33.",32,YR,,F,Y,,,20200327,,HP,PE,PE,EFAVIRENZ.,Haemophagocytic lymphohistiocytosis,175902251,HO,,,,,,,,,175902251,1,HIV infection
17590315,175903151,1,I,2008,20200313,20200327,20200327,EXP,,US-ASTELLAS-2020US010624,ASTELLAS,,,,A,M,Y,,,20200327,,CN,GB,US,SUSTIVA,Acute kidney injury;Anhedonia;Anxiety;Chronic kidney disease;Economic problem;Emotional distress;Osteopenia;Pain,175903151,OT,,,175903151,1,2008,201701,,,175903151,1,Product used for unknown indication
17591915,175919151,1,I,20161221,20200320,20200327,20200327,EXP,,US-GILEAD-2020-0456524,GILEAD,,61,YR,A,M,Y,60.7,KG,20200327,,CN,US,US,SUSTIVA,Economic problem;Osteoporosis,175919151,OT,,,175919151,1,20020808,20050321,,,175919151,1,HIV infection
17595884,175958841,1,I,,20200316,20200329,20200329,EXP,,CN-ROCHE-2574608,ROCHE,"GUO N, YANG X, SU B, WANG W, ZHANG T AND WU H FIVE CASE REPORTS OF AIDS-RELATED BURKITT LYMPHOMA AND LITERATURE REVIEW. BEIJING MEDICAL JOURNAL 2018;40(10):932-6.",31,YR,,M,Y,,,20200329,,MD,CN,CN,EFAVIRENZ.,Bone marrow disorder;Gastrointestinal fungal infection;Intentional product use issue;Off label use,175958841,OT,,,,,,,,,175958841,1,Burkitt's lymphoma
17598401,175984011,1,I,2009,20200318,20200330,20200330,EXP,,GB-MYLANLABS-2020M1032930,MYLAN,"PANOU E, WATCHORN R, BAKKOUR W, RATYNSKA M, BUNKER CB. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE. J-EUR-ACAD-DERMATOL-VENEREOL 2020;34(2):E100-E101.",35,YR,,M,Y,,,20200330,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome,175984011,OT,,,175984011,1,2009,,,,175984011,1,HIV infection
17599240,175992401,1,I,,20200323,20200330,20200330,EXP,,GB-STRIDES ARCOLAB LIMITED-2020SP004091,STRIDES,"PANOU E, WATCHORN R, BAKKOUR W, RATYNSKA M, BUNKER CB. MULTIPLE ERUPTIVE DERMATOFIBROMAS IN HIV: AN IMMUNE RECONSTITUTION ASSOCIATED DISEASE?. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY. 2020;34(2):E100-E101",35,YR,,M,Y,,,20200330,,HP,GB,GB,EFAVIRENZ.,Fibrous histiocytoma;Immune reconstitution inflammatory syndrome;Pigmentation disorder;Skin lesion,175992401,OT,,,175992401,1,2009,,,,175992401,1,HIV infection
17599576,175995761,1,I,201202,20200317,20200330,20200330,EXP,,US-DSJP-DSU-2020-110303,DAIICHI,,,,,,Y,,,20200330,,CN,US,US,EFAVIRENZ.,Acute kidney injury;Anhedonia;Anxiety;Dehydration;Diarrhoea;Emotional distress;Fanconi syndrome acquired;Nausea;Pain;Pancreatitis;Vomiting,175995761,OT,,,175995761,2,201110,20120309,,,175995761,1,Product used for unknown indication
17600360,176003601,1,I,,20200320,20200330,20200330,EXP,,FR-MYLANLABS-2020M1032592,MYLAN,,,,N,,Y,,,20200330,,HP,FR,FR,EFAVIRENZ.,Foetal exposure during pregnancy;Pachygyria,176003601,CA,,,,,,,,,176003601,1,Product used for unknown indication
17604948,176049481,1,I,201701,20200319,20200331,20200331,EXP,,PT-MYLANLABS-2020M1031681,MYLAN,SUSTAINED VIROLOGICAL SUPPRESSION AND LOW TOXICITY: THE VALUES OF COMBINATION DOLUTEGRAVIR+LAMIVUDINE.. FARMACEUTICO NEWS. 2020,45,YR,,M,Y,,,20200331,,HP,PT,PT,EFAVIRENZ.,Cardiac failure acute;Headache;Insomnia;Myalgia;Renal impairment,176049481,HO,,,176049481,1,2011,,,,176049481,1,HIV infection
4175225,417522511,11,F,,20160824,20040723,20200306,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-12645404,BRISTOL MYERS SQUIBB,,,,,M,Y,,,20200306,,HP,US,US,EFAVIRENZ.,Arnold-Chiari malformation;Congenital hydrocephalus;Foetal exposure during pregnancy;Large for dates baby;Meningomyelocele;Premature baby,417522511,HO,,,417522511,1,20030310,20040313,,,417522511,1,Product used for unknown indication
5858118,58581186,6,F,,20190603,20050811,20200306,EXP,,US-BRISTOL-MYERS SQUIBB COMPANY-13067566,BRISTOL MYERS SQUIBB,,27,YR,,F,Y,,,20200306,,HP,US,US,EFAVIRENZ.,Caesarean section;Gestational diabetes;Live birth;Pregnancy;Premature delivery,58581186,OT,,,58581186,1,20030310,20040313,,,58581186,1,HIV infection
7117171,711717113,13,F,,20200113,20090917,20200122,EXP,,CA-BRISTOL-MYERS SQUIBB COMPANY-14780902,BRISTOL MYERS SQUIBB,,52,YR,,M,Y,,,20200122,,HP,CA,CA,EFAVIRENZ.;SUSTIVA,Diplopia;Extraocular muscle paresis;Eyelid ptosis;Lipodystrophy acquired;Mitochondrial toxicity;Ophthalmoplegia;Progressive external ophthalmoplegia,711717113,OT,,,711717113,7,200802,,,,711717113,1,HIV infection
9109057,91090574,4,F,2012,20200213,20130222,20200220,EXP,,BR-VIIV HEALTHCARE LIMITED-A1012284A,VIIV,,0,YR,,F,Y,2.9,KG,20200220,,CN,US,BR,EFAVIRENZ.,Diastasis recti abdominis;Foetal exposure during pregnancy;Genital prolapse,91090574,CA,,,91090574,1,20121128,20121128,,,91090574,1,HIV infection
